Allergy diagnosis in children IgE-sensitized to peanut : clinical and immunological evaluation by Glaumann, Susanne
  
From the Department of Clinical Science and Education, Södersjukhuset 
and Sach´s Children and Youth Hospital 
Karolinska Institutet, Stockholm, Sweden 
ALLERGY DIAGNOSIS IN CHILDREN  
IgE-SENSITIZED TO PEANUT 
 
Susanne Glaumann 
 
Stockholm 2014 
 
Clinical and Immunological Evaluation 
  
 
All previously published papers were reproduced with permission from the publisher. 
Cover image by Elin Brander, www.artistica.se 
Published by Karolinska Institutet 
Printed by E-print, Stockholm, Sweden 
 
© Susanne Glaumann, 2014 
ISBN 978-91-7549-537-8 
 
  
i 
ALLERGY DIAGNOSIS IN CHILDREN IgE-SENSITIZED TO 
PEANUT-Clinical and Immunological Evaluation 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
by 
Susanne Glaumann, MD 
Principal Supervisor: 
Associate Professor Caroline Nilsson 
Karolinska Institutet 
Department of Clinical Science and Education 
Division of Södersjukhuset 
 
Co-supervisors: 
Associate Professor Anna Nopp Scheman 
Karolinska Institutet 
Department of Medicine, Solna 
Clinical Immunology and Allergy Unit 
 
Professor S.G.O. Johansson 
Karolinska Institutet 
Department of Medicine, Solna 
Clinical Immunology and Allergy Unit 
 
Professor Magnus P. Borres 
Uppsala University 
Department of Women’s and Children’s Health 
Division of Pediatrics 
Opponent: 
Professor Barbara Ballmer-Weber 
University Hospital Zürich 
Department of Dermatology 
Division of Allergy 
 
Examination Board: 
Associate Professor Lennart Nilsson 
Linköping University 
Allergy centre, Clinical and Experimental 
Medicine, Faculty of Health Science   
 
Professor Gunnar Nilsson 
Karolinska Institutet 
Department of Medicine, Solna 
Clinical Immunology and Allergy Unit 
 
Professor Catarina Almqvist Malmros 
Karolinska Institutet 
Department of Medical Epidemiology and 
Biostatistics 
 

 i 
ABSTRACT 
Background 
Peanut allergy is often life-long and affects quality of life since accidental 
ingestion may lead to severe or even fatal reactions. Sensitization to peanut can 
be due to genuine peanut allergy or to cross-sensitization due to birch pollen. 
Peanut allergy diagnosis is usually based on clinical history, skin prick test (SPT) 
and presence of IgE-antibodies (IgE-ab) to peanut but these tests often need to be 
confirmed with an oral food challenge which may cause severe allergic 
reactions. Measurements of IgE-ab to specific proteins in an allergen source 
(component resolved diagnostics [CRD]) and basophil allergen threshold 
sensitivity (CD-sens) may be valuable tools for diagnosis of peanut allergy. 
Important allergen proteins in peanut are the storage proteins: Ara h 1, Ara h 2 
and Ara h 3 and the PR-10 protein [birch-homologue] Ara h 8. 
Aim 
The aim of this thesis was to evaluate different diagnostic methods in children 
IgE-sensitized to peanut with a suspected peanut allergy. 
Method 
Paper I investigated if it is possible to predict the outcome of double-blind 
placebo-controlled food challenge (DBPCFC) with peanut by measuring CD-
sens to peanut and Ara h 2 as well as IgE-ab to peanut components (Ara h 1, Ara 
h 2, Ara h 3, Ara h 8 or Ara h 9) (n=38). In Paper II, the reproducibility of 
DBFCFC and CD-sens were investigated. Twenty-seven children underwent 
DBPCFC followed by a single-blinded food challenge with peanut, and CD-sens 
was measured before the two first peanut challenges. Paper III reports a birch 
pollen allergic child with cross-sensitization to peanut who had a severe reaction 
after eating a large amount of peanuts. The fourth paper investigated the 
outcome of a peanut challenge in relation to IgG4-ab (n=58). Paper V studied 20 
birch pollen allergic children cross-sensitized to peanut in relation to CD-sens to 
peanut and Ara h 8. 
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Results 
In Paper I, 25 children had a positive DBPCFC and 92% of the children were 
positive in CD-sens. The remaining two children were low responders and could 
not be evaluated. Children with positive DBPCFC reactions had significantly 
higher levels of IgE-ab to peanut, Ara h 1, Ara h 2 and Ara h 3 than children 
with negative reactions. All children negative in CD-sens to peanut and Ara h 2 
were also negative in challenge. In paper II, 14/27 children were positive at both 
active challenges but not placebo. Only three of these children reacted 
consistently at the same dose with the same severity score. All children with a 
positive or a negative CD-sens at the first challenge were also CD-sens 
positive/negative at the second challenge. Paper III revealed that the girl with 
birch pollen allergy who reacted with anaphylaxis after peanut ingestion was 
mono-sensitized to Ara h 8. Paper IV showed that children positive at peanut 
challenge had significantly higher levels of IgG4-ab to peanut and Ara h 2 than 
children negative at the challenge. The peanut and Ara h 2 IgG4/IgE-ab ratios 
were significantly higher in children who tolerated peanut than in allergic 
children. In Paper V, all children passed peanut challenge without any objective 
symptoms, but five experienced subjective symptoms from the oral cavity. CD-
sens to peanut was negative in 19/20 children but 17/20 were positive in CD-
sens to Ara h 8.  
Conclusion 
 CD-sens is a promising diagnostic method with good reproducibility in the 
diagnosis of peanut allergy and may exclude a peanut allergy. IgE-ab to the 
peanut storage proteins (Ara h 1, Ara h 2 and Ara h 3) seem to confirm a genuine 
peanut allergy. A peanut challenge can discriminate between positive and 
negative reactions but does not predict the severity of an allergic reaction. Birch-
pollen allergic children IgE-sensitized to peanut and Ara h 8 but not to Ara h 1, 
Ara h 2 and Ara h 3 have basophils sensitized with IgE-ab to Ara h 8 which can 
be activated by Ara h 8 proteins and initiate allergic inflammation. Children IgE- 
sensitization to peanut who nonetheless tolerate peanuts are characterized by low 
levels of IgG4-antibodies to peanut and Ara h 2 but relatively high IgG4/IgE 
antibody ratios. 
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1 INTRODUCTION 
Peanut allergy is a potentially life-threatening condition of unprecedented 
complexity and severity (1). Symptoms vary among individuals and accidental 
ingestion of peanuts may results in anaphylactic reaction, which can be fatal (2-
7). A peanut allergic individual needs to avoid a wide variety of foods containing 
peanuts, including products with precautionary labeling (8). Due to risk of severe 
reactions adrenaline auto-injectors are often prescribed. All aspects associated 
with fear of an anaphylactic reaction can impair quality of life (7, 9-12). 
Individuals IgE-sensitized to peanuts are often recommended to avoid peanuts 
irrespective of whether they have experienced allergic symptoms or not (11, 13). 
Therefore an accurate diagnosis is highly important to avoid serious 
consequences for the affected child and his or her family. A peanut allergy 
diagnosis is usually based on clinical history, skin prick test (SPT) and presence 
of IgE-antibodies (IgE-ab) to peanut in serum. However, the diagnosis often 
needs to be confirmed with an oral food challenge, preferably a double-blind 
placebo-controlled food challenge (DBPCFC), which is the gold standard (14). 
Oral food challenges are time consuming and pose a risk that the individual will 
develop a severe allergic reaction. Therefore oral challenges often need to be 
performed by specialized personnel who can handle that type of emergency. 
There are now other promising diagnostic methods, such as component resolved 
diagnostics (CRD) and CD-sens (basophil allergen threshold sensitivity). CRD 
involves investigating the presence of antibodies to different peanut allergen 
proteins. CD-sens evaluates allergen threshold sensitivity of basophils by using a 
dose-response curve measuring percentage of activated basophils at different 
concentration. This method has been shown to correlate with asthma sensitivity 
and allergic rhinitis (15-18).  
The aim of this thesis was to evaluate different diagnostic methods in children 
IgE-sensitized to peanut with a suspected diagnosis of peanut allergy. The 
terminology used in this thesis adheres to the recommended nomenclature for 
allergy from WAO 2003 (19, 20).  
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2 BACKGROUND 
2.1 FOOD ALLERGY 
Food allergy is a common disease in childhood. The condition is estimated to 
affect 12% of children in Western countries when assessed from self-reported 
symptoms and approximately 3% when based on clinical history or DBPCFC 
(21). However, prevalence reports vary worldwide depending on differences in 
allergy definitions, study populations, geographic variations and dietary 
exposure (14, 21-23). Patients often confuse food intolerance with food allergies 
and there is an unfounded belief that food allergy is more prevalent than it 
actually is. An adverse food reaction can either be immune mediated (food 
allergy) or non-immune mediated (food intolerance) as shown in Figure 1 (24).  
 
Figure 1. Types of adverse reactions to food. With permission from Boyce et al (24). 
Food intolerance is more common than genuine food allergy and is caused by the 
pharmacological properties of the food, or by defects in metabolism of certain 
food components (25). Examples of food intolerance are lactose intolerance and 
toxic reactions, such as scromboid food poisoning (from eating spoiled fish). 
Sometimes food intolerance reactions mimic an immune mediated reaction with 
symptoms such as vomiting, flushing, and stomach ache shortly after ingestion. 
An immune mediated food allergy is defined as “an adverse health effect arising 
from a specific immune response that occurs reproducibly on exposure to a 
given food”. This definition includes cell mediated, IgE-mediated, non IgE-
mediated or a combination of both IgE-mediated and non IgE-mediated allergy. 
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Example of a non IgE-mediated reaction is food protein induced enterocolitis 
syndrome (FPIES) which can present with acute symptoms such as repetitive 
emesis and dehydration a few hours after exposure. Eosinophilic esophagitis is a 
combination of both IgE-mediated and non IgE-mediated reactions and involves 
localized eosinophilic inflammation in the esophagus. Allergic contact dermatitis 
is caused by cell mediated reactions to chemical haptens that are additives to 
foods or occur naturally in foods, such as mango (24). 
This thesis focuses on IgE-mediated food allergy, which is the most common 
cause of food allergy in children. Over 170 foods have been reported to cause an 
IgE-mediated allergy; however, by far most common foods to cause allergic 
reactions are milk, egg, soy, wheat, peanut, tree nut, fish and shellfish (8, 24). A 
food allergy is seldom an isolated phenomenon and children with allergy to milk 
and/or egg in early infancy often develop additional food allergies, e.g. peanut 
(26). However, in general, it is more likely that allergies to milk, egg, soy and 
wheat resolve during childhood whereas allergy to peanut, tree nuts, fish and 
shellfish is persistent (14). 
In IgE-mediated allergy the immune system recognizes an otherwise harmless 
substance as foreign (allergen). The immune system starts to produce IgE-ab and 
the individual get sensitized to the specific allergen. Being sensitized to an 
allergen is not equal to being allergic (27, 28). However, the probability of an 
allergic reaction increases with increasing concentrations of IgE-ab but the levels 
of IgE-ab do not seem to predict the severity of an allergic reaction (8, 29).  
There are several proposed risk factors influencing food allergy and IgE-
sensitization (30). Boys have a higher risk of developing food allergy (31), 
suggesting genetic or endocrinologic influences and a child with an allergic 
parent or sibling has an increased risk to become allergic to food (30). Atopy, 
defined as a personal/familiar tendency to produce IgE-ab to otherwise harmless 
substances, is also a known risk factor for developing food allergy (19). Other 
suggested risk factors are vitamin D insufficiency, low consumption of 
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antioxidants, certain timings and routes of exposure to foods and obesity (14, 30, 
31). 
2.2 IMMUNOLOGY  
2.2.1 Overview of the immune system 
The human immune system protects the body against pathogens that range in 
size from small intracellular viruses to large parasitic organisms and has 
developed a wide range of recognition and destruction mechanisms to combat 
these diverse potential invaders (32, 33). An allergic reaction occurs if the 
immune system recognizes an otherwise harmless substance as foreign (allergen) 
and starts an immune response against the allergen (27). 
Different kinds of white blood cells are needed to produce an intact immune 
response and all these cells arise from a single cell type, hematopoietic stem cell 
(HSC) found in the bone marrow. Figure 2 shows important immune cells 
derived from the HSC. 
 
Figure 2. Hematopoiesis. 
Self-renewing hematopoietic stem cells give rise to all cells involved in an immune response. Most cells 
develop in the bone marrow and then travel to peripheral lymphoid organs. Mast cells and macrophages 
continue to mature outside the bone marrow and T-cells mature in the thymus. Modified from Chaplin et al 
and Owen et al (32, 34). 
Leukocyte
precursors
Common 
myeloid 
progenitor cell
B-cells
T-cells
Natural killer cells
(NK-cells)
NK-T cells
Common 
lymphoid
progenitor cell
CFU
(Colony-forming-unit)
Precursor cells
Megakaryocyte
precursor
Erythrocyte
precursor
Basophils
Eosinophils
Neutrophils
Platelets
Hematopoietic
stem cell
Dendritic cell
precursor
MacrophagesMonocytes
Dendritic cells
White
blood 
cells
Mast cells
Erythrocytes
Granulocytes
  
 5 
 
Granulocytes play an important role in the immune response. Neutrophils have a 
large phagocytic capability and accumulate in large quantities at sites of 
infection. They produce reactive oxygen that is cytotoxic to bacterial pathogens 
and the cells are also part of tissue remodeling following injury. Eosinophils, 
baspohils and mast cells contain mediators that are released upon activation and 
are known to protect the host from parasites and helminths but they are also 
prominent cells in most allergic responses. Monocytes and macrophages are 
highly phagocytic and are mobilized to the site of infection shortly after the 
neutrophils. They often persist at the site of infection for a long time and produce 
nitric oxide as a major mechanism of killing. Activated macrophages produce 
large amounts of proinflammatory cytokines (34).  
B-cells are the antibody-producing cells in the immune system. All B-cells 
express a membrane bound immunoglobulin molecule (with or without antibody 
activity): the B-cell receptor (BcR). The BcR has a unique antigen binding 
specificity and activated B-cells can produce large amounts of antibodies with an 
antigen-binding site identical to the BcR (32, 34). The immunoglobulins share a 
common structure of two identical light chains and two identical heavy chains 
and form a Y shape. (Figure 3) (35). All immunoglobulins are functionally 
divided into two fragments, the Fab fragment and the Fc fragment. The Fab 
fragment is the antigen binding site which is unique for each antibody. The base 
of the antibody is called the Fc region. It is 
identical for all antibodies of a given class 
and binds into Fc receptors found on 
different kinds of effector cells. There are 
five classes of immunoglobulins (IgA, IgD, 
IgG, IgE and IgM) with different functions 
in the immune system. In the circulation the 
immunoglobulin of a certain class can be 
bound together in complex (IgM circulates 
as a pentamer and IgA as a dimer). 
Figure 3. Structure of IgE-ab.  
Heavy chain (black), light chain (white)  
Modified from Gould (35). 
IgE-ab
Fc fragment
Fab fragment
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Depending on the cytokine milieu surrounding them, activated B-cells change 
their production of immunoglobulins from one class to another (class-switch) 
(34, 36).  
T-cell derived cytokines induce class-switch of the immunoglobulins produced 
by B-cells during an immune response. In the thymus T-cells mature into two 
major subpopulations, cytotoxic T-cells and T-helper cells (TH-cells). Cytotoxic 
T-cells are part of the cell mediated immune response to kill infected cells, while 
TH-cells are involved in activation of B-cells (32, 33). The largest group of T-
cells is the TH-cells. TH-cells can be activated by macrophages, dendritic cells 
and activated B-cells (antigen presenting cells [APC]). Depending on type of 
cytokine milieu at site of infection the TH-cells differentiate into different 
subpopulations and secrete a unique mixture of cytokines with distinct effector 
functions (33, 37). The different kinds of TH-cells are shown in Figure 4. 
 
 
Figure 4. Subsetting T-cell responses based on TH-cell polarization. 
T-cells becomes polarized into different effector TH-cells depending on polarizing cytokine milieu when 
activated. Modified from Swain et al (37). 
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2.2.2 Immune cells and antibodies 
Mast cells  
Mast cells are primarily located in the tissue near blood vessels and epithelial 
surfaces and are long-lived cells that can stay in the tissue for months. They are 
one of the major effector cells in IgE-mediated allergy but also of importance in 
long term pathophysiological changes and tissue remodeling associated with 
chronic inflammation (38). The mast cells express the activating receptor for 
IgE-ab (FcεRI) which is up-regulated in presence of increased concentrations of 
free IgE-molecules circulating in the blood. The biological function of mast cells 
is unknown (39). It has been suggested that these cells are involved in regulation 
of wound healing and protection from severe bacterial and parasitic skin 
infections and from reactions after severe venom insects and snake bites (40).  
Basophils 
Like mast cells, basophils play a role in allergic inflammation and the two cell 
types share several features, such as expression of FcεRI, secretion of TH2-
cytokines and histamine release on activation. Basophils are found in the 
circulation and represent <1% of peripheral blood leukocytes (41, 42). The life-
span of the basophils is short, approximately 60 hours, but increases during 
inflammation (43).The percentage of circulating basophils among different 
individuals varies but there is currently no evidence that an increased number of 
circulating basophils correlates with allergic diseases (44). Even though the 
basophils share many features with mast cells, they represent a distinct cell 
lineage and are not a population of immature circulating mast cells (45). 
Basophils are known to have a strong association with helminth infections but 
also with TH2 associated diseases. They are involved in delayed-type 
hypersensitivity reactions in humans; they infiltrate the tissue following acute 
allergic reactions and are for example found in the lungs in severe asthma, in the 
upper respiratory tract in individuals with allergic rhinitis and in the skin of 
individuals with atopic eczema (44). The basophils also represent an important 
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source of interleukin (IL)-4 / IL-13 and secrete histamine, proteases and 
leukotrienes -all of central importance in promoting allergic inflammation and 
allergic disease (42, 44, 46, 47).  
IgE-antibodies 
IgE was discovered simultaneously in 1967 by one Swedish and one American 
research group working independently (48, 49). The discovery was a 
breakthrough and had great impact on our understanding of the immunological 
basis of allergic diseases (50). 
IgE-ab is an important mediator in allergic inflammation and its production is 
promoted by IL-4/IL-13, both of which are produced during a TH2-dependent 
response. The concentration of IgE in serum is low compared to other 
immunoglobulins and its half-life is short, approximately two days. Expression 
of IgE-ab is normally strictly regulated but the concentration is elevated in atopic 
and allergic individuals (46). There are two IgE-receptors: the low affinity 
receptor FcεRII (CD23) and the high affinity receptor FcεRI. The latter is 
expressed on both mast cells and basophils and has a crucial role in allergic 
inflammation. The half-life of an unbound FcεRI on a mast cell is 24 hour in 
vitro. However, the in vitro half-life of the IgE-FcεRI complex is considerably 
longer and it appears to be expressed on the mast cells throughout the whole life 
span of the cell. The low affinity receptor (FcεRII) is expressed on B-cells and 
other hematopoietic cells, for example APC and intestinal epithelial cells. 
Activation of the low affinity receptor leads to regulation of IgE-production, 
killing of intracellular pathogens and facilitation of antigen presentation (38, 46).  
IgG4-antibodies 
IgG is the most common immunoglobulin in human. It is divided into four 
subclasses (IgG1, IgG2, IgG3, IgG4) of which IgG4 is the least abundant (<5%). 
The association of IgG4 with IgE-mediated allergic inflammation is known, but 
its exact role is poorly understood (51). It has been hypothesized that IgG4-ab act 
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as blockers, binding to the allergen and inhibiting binding between the allergen 
and IgE-ab (52, 53). IgG4-ab can also bind to the low affinity IgG-receptor 
(FcγIIB) on mast cells and basophils, leading to inhibition of cell degranulation 
(54, 55).  
2.2.3 IgE-mediated allergic inflammation 
In IgE-mediated allergy, the immune system responds to an otherwise harmless 
substance in an inappropriate way involving both TH2-cell response and IgE-ab. 
The reaction resembles the immune response to helminths and parasites which 
has led to the idea that the immune system is deceived to react to otherwise 
harmless antigens in the same way as it responds to helminth infections. After 
the individual has been sensitized and started to produce IgE-ab, an allergic 
reaction can occur. The reaction is divided into an acute IgE-mediated response 
and a late phase response. After the initial exposure (sensitization) the immune 
system has primed mast cells and basophils with IgE-ab and they are ready to 
start an allergic inflammation if re-exposed to the allergen (22, 27, 56). 
Sensitization and the acute phase of an allergic reaction are described in  
Figure 5. Some individuals also develop a late phase response which typically 
develops two to six hours after the initial reaction (57). During the IgE-ab 
mediated activation, mast cells and basophils produce a wide range of cytokines, 
chemokines and growth factors but these are released more slowly than the 
preformed mediators. The newly produced cytokines facilitate the influx of more 
TH-cells (which change the cytokine environment), monocytes, eosinophils, 
basophils and neutrophils, causing mucus secretion, vasodilatation, increased 
vascular permeability, constriction of the bronchi and tissue remodeling (22, 
57).The late phase response often peaks after six to nine hours. 
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Figure 5. Mechanism of acute IgE-mediated allergic inflammation. 
1) Sensitization: The allergen penetrates the mucosa and is internalized by 
antigen presenting cells (APC) through phagocytosis. The allergen is degraded 
to peptides in the APC and presented to the TH2-cells through MHC II molecules 
on the cell surface. Activation of the naïve TH2-cell occurs if the TH2-cell is 
activated by three signals: 1) Recognition between the TcR and the MHC II 
molecule. 2) Co-stimulatory interaction between T-cell and APC. 3) Paracrine 
secretion of cytokines by APC. Once activated, the effector TH2-cell activates the 
B-cell and secretes cytokines (IL-4/ IL-13) which induces class switch in B-cells 
to IgE-ab production. IgE-ab binds to high affinity receptor (FcεRI) on mast 
cells and basophils for a faster response on re-exposure to the allergen.  
2) Acute effector phase: On re-exposure to the allergen, cross-linking of the 
FcεRI-IgE-ab complex binds to the allergen and activates mast cells and 
basophils, which then release mediators (e.g. histamine, cytokines, leukotrienes, 
prostaglandins, proteolytic enzymes) leading to inflammation and tissue damage 
(22, 27, 56). 
B-cell activation
2. Co stimulatory
interaction
1. TcR
signaling 
3. Cytokine 
signaling 
Presentation/T-cell activation
Cytokine 
signaling 
IL-4/IL-13
Class switch to IgE-ab/
Clonal expansion
B-cell
basophil
Sensitization
mast cell
IgE-ab /FcεRI
FcεRI
FcεRI
IgE-ab /FcεRI
TH2-cellTH2-cell
2) Acute effector phase
mast cell
IgE-ab /FcεRI
FcεRI
Cross-linking FcεRI
Food 
allergen
basophil
Degranulation
release of inflammatory mediators
(histamine, leukotrienes, proteases)
LYMPH NODE
APC
Food
allergen
Recognition
APC
Re-exposure to 
food allergen
1) Sensitization
TcR
MHC II
TISSUE
TISSUE/CIRCULATION
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2.3 PLANT FOOD ALLERGENS  
Allergen proteins are classified into families and super-families according to 
structural and functional features. Many food allergens belong to the cupin and 
prolamin super-families. The cupin super-family (7S and 11S storage seeds 
proteins) is divided into vicilin and legumin protein families where soybean, 
peanut and tree nut seed storage proteins are found. The prolamin super-family is 
divided into three major groups: the seed storage 2S albumins found in tree nuts 
and seeds, the non-specific lipid transfer proteins (LTP) found in soft fruits and 
vegetables and cereal α-amylase/trypsin inhibitors (58, 59).  
The pathogenesis-related proteins (PRs) are a heterogonous collection of 14 
plant protein families which are involved in plant resistance to pathogens. Many 
plant food allergens are homologous to PRs (59). The major birch pollen 
allergen, Bet v 1, is a member of the PR-10 family and birch pollen allergic 
individuals may experience symptoms from the oral cavity known as oral allergy 
syndrome (OAS) when they eat certain plant foods. The majority of these 
reactions occur after consumption of allergens of the Rosaceae fruits (e.g. apple, 
apricots and pears) or Apiaceae vegetables (e.g. celery and carrots), which cross-
react with allergens presented in pollen from birch (Bet v 1) and other trees. 
Peanut contains Ara h 8, which is a Bet v 1 related allergen and a member of the 
PR-10 family (58). This is the reason why birch pollen allergic individuals also 
may experience OAS when eating peanuts. 
2.4 PEANUT ALLERGY 
Peanut allergy is a serious health concern affecting both children and adults. 
Despite the risk for severe reaction there is currently no treatment; instead a strict 
diet without peanuts is recommended (60, 61). Peanut allergy is also often 
persistent. Only 20% of the individuals allergic to peanut grow out of their 
allergy and even if they do, it sometimes recurs (61). Co-morbidity with other 
allergy diseases is common and less than 5% of patients have mono-sensitization 
to peanut. Peanut allergic individuals are also often atopic and their rates of 
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asthma, atopic eczema and rhinitis are higher than in the general population (1, 
61, 62). 
Peanut sensitization is common and several studies indicate that the prevalence is 
rising (14, 63-67). IgE-sensitization to peanut varies in different studies, from 
1% -11% in Western countries and for challenge-proved peanut allergy the 
prevalence ranges between 0.2 and 1.6% (21, 68, 69) 
Clinical presentation and severity of peanut allergy 
Symptoms of an IgE-mediated peanut allergy can occur within minutes after 
exposure, but the reaction can also have a slower onset with up to two hours 
delay (24). Symptoms 
range from mild to life-
threatening anaphylactic 
reaction. Common 
symptoms are listed in 
Table 1. Acute urticaria 
and angioedema are 
common clinical 
manifestations which may 
be triggered by ingestion 
or by direct contact with 
the skin, the latter causing 
acute contact urticaria. 
Even though hives and 
swelling are common 
symptoms of an allergic 
reaction, severe reactions 
do not necessarily include 
urticaria. Twenty percent 
of anaphylactic reactions 
Table 1. Symptoms  in IgE-mediated allergy reaction.  
With permission from Boyce et al (24). 
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do not involve the skin (70). Symptoms from the lower airways, presenting as 
cough, wheezing and/or dyspnea, could be a sign of a more general allergic 
reaction. Rhinoconjunctivitis is often observed but rarely as the only presenting 
symptom (71). Gastrointestinal manifestations are often associated with IgE-
mediated food allergy and include pruritus and swelling of the mouth, abdominal 
pain or cramps, vomiting and diarrhea (24). Upper gastric manifestations often 
occur early after ingestion whereas low gastric symptoms may be delayed up to 
two to six hours (71). 
Anaphylaxis is a severe and potentially life-threatening systemic allergic 
reaction. It is defined as presence of symptoms from two or more organ systems 
after exposure to a likely allergen or hypotension alone after exposure to a 
known allergen. Anaphylaxis can be biphasic in up to 20% of the reactions and 
this pattern is more common in severe cases (72). Even though fatal reactions are 
uncommon they pose a potential risk, especially for teenagers and young adults 
with co-morbidity of asthma and peanut or tree nut allergy (3, 73). Other related 
factors often associated with near fatal or fatal reactions are delayed treatment 
with epinephrine, absence of skin symptoms, patient denial of symptoms and 
concomitant use of alcohol (2, 3, 6, 71, 74). Foods are the most common cause 
of anaphylactic reactions (75). This is in line with a Swedish population-based 
case study investigating anaphylaxis among children 0-18 years at emergency 
departments in Stockholm. The authors concluded that food was the triggering 
factor in 92% of the cases and that tree nuts, peanuts, egg and milk were the 
foods that most frequently elicit anaphylaxis in children (76).  
Oral allergy syndrome (OAS) is an IgE-mediated reaction, typically observed in 
patients allergic to pollen, after ingestion of certain fresh fruits, vegetables, 
peanuts and tree nuts (77, 78). Symptoms such as itching, stinging pain and 
vascular edema are restricted to the oral cavity. Itching in the ears and tightness 
of the throat may occur but the symptoms usually gradually resolve after 
exposure without treatment (78). OAS is sometimes referred to by the more 
specific term pollen-food allergy syndrome (PFS) (79, 80).  
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2.5 COMMON DIAGNOSTIC METHODS IN PEANUT ALLERGY 
The first step when diagnosing a peanut allergy is to take a detailed medical 
history and do a physical examination. It is important to exclude other causes of 
an adverse reaction than IgE-mediated allergy (Figure 1). If the clinical history 
provides a strong suspicion of IgE-mediated allergy, laboratory methods can be 
used to identify presence of IgE-abs. The most widely recommended diagnostic 
methods are skin prick test (SPT), IgE-ab measurements in serum and oral food 
challenges (8, 24, 81-83). During the last decade, new diagnostic methods have 
become available, such as CRD and CD-sens. 
2.5.1 Skin prick test 
SPT is a quick, inexpensive test utilizing the degree of cutaneous reactivity as a 
marker for sensitivity. When an allergen is inserted into the skin in a sensitized 
individual, IgE-ab bound to the mast cells are cross-linked and histamine and 
other mediators are released. This produces a wheal and flare response (84). A 
SPT is considered positive if the wheal diameter is larger than 3 mm. Compared 
to oral challenges, the pooled sensitivity for SPT to peanut is estimated to 95% 
(88-98%) and the specificity to 61% (47-74%) (85). However, in pollen related 
food allergy (e.g. celery, carrots, cherries and hazelnuts) the sensitivity of SPT is 
much lower (20-65%) (86). The source of the allergen used for SPT may also 
influence the wheal size. Different batches of commercial allergen extracts may 
contain different amounts of protein, affecting the allergenicity and the potency 
of the extract (84, 86, 87). However, it is also possible to perform a prick-prick 
test where native allergens (e.g. a fresh fruit) are used instead of commercial 
extracts. The procedure of a prick-prick test is: one prick in the fresh food and 
then a prick in the patient’s skin (88). The overall concordance between a 
positive prick-prick test and a food challenge was 92% when fresh food was 
used in comparison with 59% with commercial extracts (89).  
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2.5.2 IgE-ab assays 
IgE-ab assays detect and measure circulating IgE-ab that binds to specific 
allergens in a patient’s serum. The IgE-ab assay is described in Figure 6. There 
are different detection systems for IgE-ab in serum, e.g. HYTEC-288 
(HycorBiomedical), Immulite (Siemens) and ImmunoCAP (Phadia). The amount 
of IgE-ab bound in the assay is reported in arbitrary mass units (kilo international 
units of allergen specific antibodies per unit volume of sample [kUA/L]). 
In the ImmunoCAP system, one international unit is equal to 2.42 ng of IgE-ab. 
No conversion ratio has been established in the other systems (90, 91). The 
analytical sensitivity (lower 
limit of quantification 
[LLOQ]) is today 0.1 kUA/L 
in all three systems but it 
should be pointed out that a 
result from an allergen in one 
system is not equivalent in 
another system (92). 
The pooled sensitivity to 
peanut IgE-ab is 96% (92-
98%) and the pooled 
specificity is 59% (45-72%) 
compared to oral challenges. 
The results obtained with 
pooled sensitivity and 
specificity are similar to those 
from SPT, with a high 
sensitivity but poor 
specificity (85). 
 Figure 6. Basic principles for IgE-ab assays. With permission from Cox et al (91). 
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SPT vs. IgE-ab assay 
Serum IgE-ab assays and SPT have similar diagnostic properties. They can both 
detect sensitization to an allergen. There is also a correlation between increasing 
concentration of IgE-ab in serum and SPT wheal size and the probability to react 
to the ingested food (8, 23, 29, 93).  
Compared to SPT, IgE-ab assays are a more expensive method but on the other 
hand the IgE-ab assay does not interfere with severe eczema and the test result is 
not affected by antihistamine intake (92, 94). Another disadvantage for SPT is 
that the results may differ depending on use of different skin test devices and 
techniques (95).  
Peanut allergen extract 
Peanut extract is commonly used for SPT or IgE-ab assay in the diagnostic 
work-up for peanut allergy. A benefit of using natural extracts are that ideally all 
allergenic proteins are present but allergen extract has two main disadvantages. 
First it is difficult to standardize; natural variability makes extracts differ in 
allergenicity (28, 96, 97). Second, peanut allergen extract does not differentiate 
between primary sensitization and immunological cross-reactivity (98). 
2.5.3 Oral food challenge 
An oral food challenge is performed to make an accurate diagnosis of adverse 
reaction to foods (99-103). The challenge can be performed open or blinded and 
the double-blind placebo-controlled food challenge (DBPCF) is the gold 
standard. Open food challenge (OFC) is an unmasked challenge with foods in 
their natural form. An OFC saves time compared to DBPCFC and is often used 
in clinical practice, particularly since 2/3 of all food challenges are negative (99, 
100). A negative OFC can rule out an adverse reaction but a positive test needs 
to be confirmed with a blinded challenge. A blinded challenge can either be a 
single-blind food challenge (SBFC) or a DBPCFC. In a SBFC the personnel but 
not the patients know whether active or placebo food is being served. DBPCFC 
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is often used for research purposes or when an OFC is not sufficient to rule out a 
food allergy. At a DBPCFC neither the patient/family nor the personnel know 
whether the active or placebo food is being served (99, 101).  
A food challenge should be performed under medical supervision and without 
any medication that can mask symptoms, e.g. oral steroids or antihistamines. 
Challenges with high risk for a reaction should be done in hospital settings with 
intravenous access. The start dose of a challenge should be low (<100 mg), 
followed by increasing doses every 20-30 minutes. The challenge should be 
stopped when objective symptoms occurs (101). A scoring system for severity of 
food challenge outcome has been recommended in the consensus report for 
standardizing of oral food challenge from 2012 (101). Unfortunately, this scoring 
system does not combine the severity of the challenge reaction and the amount 
of peanut eaten. 
2.6 COMPONENT RESOLVED DIAGNOSTICS 
CRD, also known as molecular-based allergy (MA) diagnosis, involves using 
purified, native or recombinant allergen to detect IgE-sensitization to different 
proteins in an allergen source (104). An allergen source (e.g. crude peanut) 
contains many different proteins and some of them are associated with allergic 
reactions. However, many different proteins share common epitopes (binding 
site for ab) and the same IgE-ab can bind and cause an immune response to 
proteins with similar structures from other sources (cross-reaction).The stability 
of a protein also differs during exposure to heat and digestion, which explain 
why some allergens are tolerated raw while others need to be cooked to be 
tolerated (98, 104). Proteins in an allergen extract are defined as a major allergen 
if IgE-ab binds to the protein in more than 50% of the patients with the same 
allergy. A primary allergen is the original sensitization molecule, in contrast to 
secondary sensitization caused by cross-reactivity (104). Through knowledge 
about different protein structure and protein stability it might be possible to 
differentiate genuine allergic reactions from cross-reactive sensitization (98, 
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104). Allergenic proteins are designated by their Latin name (genus and species). 
For example, an allergen that come from Arachis hypogaea (peanut) is named 
Ara h and a number is used to distinguish various allergens from the same 
species (e.g. Ara h 1, Ara h 2, Ara h 3) (104).  
Peanut components 
Twelve peanut allergen proteins have so far been discovered and all are listed in 
the International Union of Immunological Societies Allergen Nomenclature 
Subcommittee Database (www.allergen.org) (59, 105, 106). Six of these peanut 
allergens are investigated in this thesis and type of allergen, biological function 
and known cross-reactivity are listed in Table 2.  
Table 2. Peanut allergens  
*LTP Lipid transfer protein. Modified from Bublin et al (105). 
 
The clinically most important peanut proteins were discovered by Burks and 
colleagues. Ara h 1 and Ara h 2 were identified in the beginning of 1990s and 
Ara h 3 and Ara h 8 were discovered a couple of years later (107-110). The 
major proteins causing severe allergic reactions are Ara h 1, Ara h 2 and Ara h 3 
(111, 112). However, there are geographic differences and all patients do not 
necessarily react similarly or recognize the same allergens (113). IgE-
sensitization to peanut due to cross-sensitization between the major birch pollen 
allergen Bet v 1 and the peanut allergen Ara h 8 is common in birch-rich areas 
(68, 69, 113) whereas sensitization to Ara h 9, a member of the LTP allergen 
Protein 
superfamily Cupin Prolamin Bet v 1 like
Protein 
family
Vilicin or 
7S Globulin
Legumin or 
11S Globulin 2S Albumins LTP* Bet v 1 family
Allergen Ara h 1 Ara h 3 Ara h 2 Ara h 6 Ara h 9 Ara h 8
Biological 
function
provide nourishment for the growth 
of seedlings
sources of amino acid for growth 
of seedlings, involved in defense 
against pathogens
involved in defense 
against pathogens and 
in the formation of 
hydrophobic layers in 
plants
might serve as a 
delivery vehicle for 
flavonoids
Cross-
reactivity
with other
legumes and 
tree nuts vilicins, 
and Ara h 2 and 
Ara h 3
with other
legumes and 
tree nuts
legumin and 
Ara h 1, Ara h 2 
and Ara h 6
with 2 S 
albumins from 
almond, brazil 
nut, and Ara h 
1, Ara h 3 and 
Ara h 6.
with Ara h 1, 
Ara h 2 and 
Ara h 3
with peach and 
hazelnut LTPs
(Pru p 3 and Cor a 8)
with Bet v 1 and 
other PR-10 
proteins e.g. soy 
and lentil
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family, plays an important role in patients from the Mediterranean area (113, 
114). The known peanut allergen classes constitute 85% of the total protein 
content of peanut and most (75%) consists of Ara h 1, Ara h 2 and Ara h 3 
proteins (115). 
2.7 BASOPHIL ACTIVATION 
Basophil activation test (BAT) is a functional test investigating basophil 
activation after exposure to an allergen (116, 117). Basophil function can be 
tested by using two different methodologies. It is possible to investigate 
secretion of mediators from basophils (mediator release assays) or by detecting 
expression of cellular markers after stimulation (flow cytometric assays). The 
most well-known method of testing mediator release is the histamine release test 
which relies on presence of preformed histamine in granules of basophils. The 
basophil response is quantified as the amount of histamine released as a 
percentage of the total histamine content (118). Flow cytometric assays are based 
on unique surface markers, e.g. CD63 or CD203c, that are expressed on 
basophils and can be measured with flow cytometry (119). In a resting basophil, 
CD63 is located inside the cell granules. Upon activation, granules fuse with the 
cell membrane and CD63 will be exposed on the cell surface (120). CD203c, on 
the other hand, is constitutively expressed at low levels on the surface membrane 
in resting basophils and is quickly up-regulated upon cell activation (121). 
Activation of basophils is shown in Figure 7. 
Figure 7.  Activation of basophils.  
In resting sensitized basophils, CD203c 
is expressed on the surface together 
with IgE-antibodies bound to the FcεRI 
receptor. Activation occurs after cross-
linking of FcεRI-IgE-ab with the 
allergen and results in degranulation 
and release of mediators, e.g. 
histamine. CD203c is further up-
regulated and CD63 will be expressed 
on the cell surface. 
CD203c
histamine
CD63
CD203c
CD63
allergen
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Depending on how basophils are stimulated by an allergen, basophil reactivity 
vs. basophil sensitivity will be measured (119). Basophil reactivity tests measure 
the maximal response of the basophils at one allergen concentration while 
basophil sensitivity tests investigate the basophils’ allergen sensitivity. An 
important aspect in analyzing basophil sensitivity is the allergen dose-response 
curve. The dose-response curve of IgE-mediated responses in human basophils 
needs several 10-fold dilutions since there is a large variability of basophil 
sensitivity and responsiveness to the same allergen in different individuals (122). 
There is one study reporting that 10-20% of the human population are non-
responders, e.g. their basophils do not respond upon activation (123). Our 
clinical experience indicates a lower figure of approximately 5-10 % (124). 
However, in individuals with non-reacting basophils it is not possible to use any 
basophil activation test. 
The method used in this thesis is basophil allergen threshold sensitivity test  
(CD-sens) (15). CD-sens is a functional in vitro test that determines the allergen 
threshold sensitivity, i.e. the lowest allergen dose that gives a 50% CD63 
activation of the basophils. Thus activation of basophils at lower concentrations 
corresponds to high allergen sensitivity. Clinical research studies have shown 
good correlation between CD-sens, SPT, IgE-ab levels and allergic rhinitis 
Studies investigating allergen sensitivity of patients with allergic asthma and 
showed also a good correlation with CD-sens (15-18). 
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3 OBJECTIVES 
 
3.1 GENERAL OBJECTIVES 
The general objective of this thesis was to evaluate children IgE-sensitized to 
peanut with a suspected IgE-mediated peanut allergy both clinically and 
immunologically with different diagnostic methods.  
3.2 SPECIFIC OBJECTIVES 
The specific objectives were:  
• To evaluate CD-sens to peanut and Ara h 2 in relation to the outcome of 
DBPCFC in peanut sensitized children. 
 
• To investigate if concentrations of IgE-ab to peanut, Ara h 1, Ara h 2, 
Ara h 3, Ara h 8 and Ara h 9 can predict the outcome of a DBPCFC. 
 
• To study the reproducibility of oral food challenge regarding severity of 
reactions and eliciting dose and compare the reproducibility with the 
 CD-sens method. 
 
• To evaluate if concentrations of IgG4-antibodies to peanut, Ara h 1, 
Ara h 2, Ara h 3 and Ara h 8 correlate to the outcome of oral peanut 
challenges. 
  
• To investigate CD-sens to peanut and Ara h 8 in relation to oral peanut 
challenge in children IgE-sensitized to peanut, birch and Ara h 8. 
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4 MATERIAL AND METHODS 
4.1 STUDY POPULATION AND STUDY DESIGN 
Study subjects from two different populations are included in this thesis. The 
two first papers (I and II) are based on subjects from Sach’s Children and Youth 
Hospital, Stockholm, Sweden (study population 1). Paper III is a case report of a 
child from study population 1. The fourth paper is based on subjects both from 
Sach’s Children and Youth Hospital and from the 8-year follow-up of the 
BAMSE Cohort (study population 2). Paper V includes patients from study 
population 2. The number of patients and inclusion/exclusion criteria in the 
different studies/papers are presented in Figure 8.  
 
Figure 8. Study population 1 and 2 in relation to the five different papers in the thesis.  
 
Paper I
Children with a 
suspected peanut 
allergy, IgE-ab to 
peanut (> 0.35 kUA/L) 
or a positive skin-
prick-test (SPT)
(≥ 3 mm)
n= 38
Patients referred to Sach’s Children and Youth 
Hospital with a suspected peanut allergy.
Sensitized to IgE-ab peanut  (>0.35 kUA/L) 
or a positive SPT
n=43
20 randomly selected 
n=20
Sensitized to brich, peanut and Ara h 8 (>0.35 kUA/L) but 
not to Ara h 1, Ara h 2 or Ara h 3 (<0.35 kUA/L) 
n= 160
Patients included in the data analysis
n=38
Paper III
Case report
Birch pollen allergic 
child with sensitization 
to  Ara h 8 but not to Ara 
h 1, Ara h 2 or Ara h 3
n=1
Paper II
Children with a suspected 
peanut allergy, IgE-ab to 
peanut (> 0.35 kUA/L) or a 
positive skin- prick-test (SPT) 
(≥ 3 mm) with two positive 
peanut challenges
n=27
Paper IV 
Children with a 
suspected peanut 
allergy, IgE-ab to peanut 
(> 0.35 kUA/L) or a 
positive skin- prick-test 
(SPT) (≥ 3 mm).
n= 58
Patients with a suspected peanut allergy avoiding 
peanut.
n=62
Loss of follow-up/
not possible to reach 
n=16
Paper V
Birch pollen allergic children 
with a suspected peanut allergy 
and sensitization to Ara h 8 but 
not to Ara h 1, Ara h 2 or Ara h 3
n= 20
5 patients excluded
Reported no symptoms at 
age of 8 in the BAMSE 
cohort, Not contacted 
n=47 
Consuming peanuts during
the last 12 months. Considered
peanut tolerant
n=35 
BAMSE survey 
8-years follow up 
n=62 
Sach’s Children and Youth Hospital
Allergy department 
n=98
STUDY  POPULATION 2
STUDY POPULATION 1
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Sach’s Children and Youth Hospital is one of two children’s hospital in the 
Stockholm area. The Allergy department at the hospital has a food allergy unit 
that diagnoses and treats children with moderate to severe food allergy. 
The BAMSE survey (n=4089) is an on-going population based birth cohort from 
predefined areas in Stockholm aiming at examining risk factors for allergy 
related diseases in childhood (125).  
4.1.1 Study population 1  
Forty-three children, aged 4-19 years, were invited to participate. The children 
were referred to the Allergy Department, Sach’s Children and Youth Hospital 
due to a suspected peanut allergy.  
Inclusion criteria were:  
- IgE-ab to peanut (> 0.35 kUA/L) and/or a positive SPT to peanut (>3mm).  
- Avoidance of peanuts for at least four weeks prior to inclusion. 
Exclusion criteria were:  
- History of anaphylaxis grade II-III to peanut confirmed in medical records. 
Figure 9 describes the study design used with study population 1. 
 
Figure 9. Study design study population 1.  
 
Children with a suspected peanut allergy, IgE-ab to peanut (>0.35 kUA/L) and /or 
a positive SPT to peanut (>3mm)
n=38
SBFC
Peanut
n=27
Clinical evaluation
DBPCFC
Peanut/placebo
n=38
Blood samples
IgG4-ab to peanut, Ara h 1, 
Ara h 2, Ara h 3, Ara h 8, Ara h 9
IgE-ab to peanut, Ara h 1, 
Ara h 2, h 3, Ara h 8, Ara h 9
CD-sens to peanut and Ara h 2
DBPCFC
Peanut/placebo
n=38
Blood samples CD-sens to peanut and Ara h 2
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Five children were excluded from the data analysis (Paper I, II and IV). One 
child did not complete the study, two other children did not follow the study 
protocol and the last two were found not to fulfill the inclusion criteria. Up to 
three challenges were performed, the first two were either placebo or active in 
random order and the third challenge was always active for ethical reasons. 
Venous blood samples were drawn before the first and second challenge for 
blood analysis.  
4.1.2 Study population 2 
Twenty children, 5-18 years, IgE-sensitized to birch and peanut, with a suspected 
peanut allergy were included. All children were part of another larger study at 
the Allergy Department, Sach’s Children and Youth Hospital (n=160) (126). The 
children in the present study were randomly selected by inviting the first two 
study subjects each week that came to the clinic for an oral peanut challenge. All 
patients were IgE-sensitized to birch, peanut and Ara h 8 (> 0.35 kUA/L) but not 
to Ara h 1, Ara h 2 and Ara h 3 (< 0.35 kUA/L). Children were not included if 
they had a history of anaphylaxis grade II-III to peanut confirmed in medical 
records. Figure 10 describes the study design used with study population 2. 
 
Figure 10. Study design study population 2.  
 
Children with a suspected peanut allergy, IgE-sensitized to birch, 
peanut and Ara h 8 (>0.35 kUA/L) but not to Ara h 1, Ara h 2 or Ara h 
3 (<0.35 kUA/L
n=20
OFC Blood samples
IgG4-ab to peanut, Ara h 1, 
Ara h 2, h 3, Ara h 8
IgE-ab to peanut, Ara h 1, 
Ara h 2, Ara h 3, Ara h 8 and Gly m 4
CD-sens to peanut, Ara h 8 
and Gly m 4
Clinical evaluation
Positive  in challenge Negative in challenge
DBPCFC
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Since only two of the children in study population 2 were recruited from the 8-
year follow-up of the BAMSE cohort, this birth cohort will not be further 
discussed in this thesis. Information about the BAMSE cohort can be found 
elsewhere (125). An OFC to peanut was performed and if objective symptoms 
occurred a DBPCFC was scheduled. All blood samples were drawn before the 
OFC. 
4.2 STUDY METHODS 
4.2.1 Study subject characteristics 
Medical records 
Paper I, II, IV and V: Doctors’ diagnosis of asthma, hay fever, eczema and food 
allergy was based on the International Classification of Disease, tenth revision 
(ICD-10) and collected from medical records. 
In children reporting previous reactions to peanut, medical records were also 
used to collect information and evaluate the severity of the allergic reaction.  
Paper III: After permission from the patient and her parents’, information about 
the clinical history and laboratory results was collected from the patient’s 
medical record at Sach’s Children and Youth Hospital and from the Emergency 
clinic at Södertälje Hospital.  
Clinical investigations 
Paper I, II, IV and V: A medical history with focus on peanut allergy and 
medications was taken before the peanut challenges. Heart and lung auscultation, 
blood pressure measurements, and inspection of the oral cavity and skin were 
done before and during the challenges.  
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Telephone interview  
Paper III: The patient’s mother was interviewed over the telephone to collect 
more information about the patient’s systemic reaction to peanut.  
4.2.2 IgE-antibodies and IgG4-antibodies 
During the time-span of these research projects, laboratory techniques have 
developed and the Lower Limit of Quantification (LLOQ) for IgE-ab analysis 
has decreased from 0.35 kUA/L to 0.1 kUA/L. Therefore an IgE-ab level >0.35 
kUA/L was used at the inclusion to define a positive test.  
Paper I, III-V: Circulating IgE and IgE-ab to birch (Betula verrucosa), peanut 
(Arachis hypogaea), Ara h 1, Ara h 2, Ara h 3, Ara h 8, Ara h 9, Bet v 1 and Gly 
m 4 were measured in serum with the ImmunoCAP® test (Phadia, Uppsala, 
Sweden). A positive test was defined as an IgE-ab level >0.1 kUA/L.  
Paper I: IgE-ab as a percentage of total IgE was calculated and designated “IgE-
ab fraction”. 
Paper III: The recombinant 2 S albumin IgE-ab to Ara h 6 (sequence Acc. No. 
Q647G9) was analyzed at Thermo Fisher Scientific Diagnostic, Uppsala, 
Sweden, using an experimental ImmunoCAP® test (127). A positive test was 
defined as an IgE-ab level >0.1 kUA/L. 
Paper IV: IgG4-ab to Ara h 1, Ara h 2, Ara h 3 and Ara h 8 in serum were 
measured with the ImmunoCAP® test. A positive test was defined as an IgG4-ab 
level >0.07 mg/L. 
4.2.3 CD-sens method 
Blood samples were stored at +4°C for a maximum of 24 hours before cell 
analyses. Basophils from whole blood are stimulated with decreasing 
concentrations of an allergen. The basophils were stimulated with decreasing 
concentrations of desalted roasted peanut extract (final concentration 2.5-2500 
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ng/ml) recombinant Ara h 8 (final concentration 0.05-500 ng/mL) and Gly m 4 
(final concentration 0.05-500 ng/mL) (Thermo Fisher Scientific, Uppsala, 
Sweden). Anti-FcεRI [IgE-dependent pathway] (Bühlmann Laboratories AG, 
Schönenbuch, Switzerland) and N-formyl-methionyl-leucyl-phenylalanin, fMLP 
[IgE-independent pathway] (Sigma Chemical Co, St. Louis, MO, USA) are used 
as positive controls and stimulated basophils are stained for CD63 and CD203c 
expression (Immunotech, Marseille, France). Cell surface expression of CD203c 
is used for identification of basophils and CD63 for detection of activated 
basophils. The basophils are finally analyzed in a Navios flow cytometer 
(Beckman Coulter, Inc., Fullerton, CA, USA). A detailed description of the CD-
sens method is found in Figure 11. 
 
Figure 11. CD-sens method. Small volumes of blood (100 µl) are incubated at +37ºC for 20 min with 
several dilutions of an allergen. An antibody is used as positive control. A phycoerythrin (PE) conjugated 
anti-CD203c mAb is used for identification of basophils and a fluorescein isothiocyanate (FITC) conjugated 
anti-CD63 mAb is used for detection of basophil activation. Following allergen stimulation the two 
conjugated antibodies are added and incubated for 25 min at +4ºC. This is followed by lysis of the 
erythrocytes. The remaining leukocytes are washed and re-suspended in phosphate buffered saline (PBS). 
Surface CD203 and CD63 expression is measured by two-color flow cytometry. 
Positive
control
Negative
control
Whole blood
Diluted allergen
CD63
CD203c
Metod
8-10 tubes with 100 µl whole blood + 100 µl of each allergen dilution to each tube 
(ten-fold dilutions of the allergen covering a broad concentration range)
Two tubes with positive controls (anti-FcεRI and fMLP) 
One tube with a negative control (RPMI)
Incubation 20 minutes at +37oC
Put on ice for 5 min.
Add conjugated CD63-antibodies (for detection of activated basophils)
and CD203c antibodies (for identification of basophils) to each tube.
Incubate 25 minutes on ice, protected from light
Hemolysis of erythrocytes, wash and resuspened in PBS 
Flow cytometric analyses
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The cut-off determining a positive test was set to 5%, i.e. twice the background. 
Individuals whose basophils responded with 0-5% CD63-upreglation after 
stimulation with anti-FcεRI, i.e. the positive control, are regarded as non-
responders (14, 120). For individuals with a response between 5-16 % (low 
responders) the results should be interpreted with caution. The cut off 16% was 
calculated (mean 76% -3SD) from the positive controls of an in-house reference 
material from 264 allergic children and adults. The result from a CD-sens 
analysis is presented as a dose response curve as shown in Figure 12. CD-sens is 
measured as the lowest allergen concentration causing 50% of the maximum up-
regulation of CD63 (LC50) and is defined as the inverted value of LC50 
multiplied by 100 [100(1/LC50)]. A high CD-sens indicates a high basophil 
allergen threshold sensitivity (15).  
 
Figure 12. Dose–response curve. A dose-response curve from a CD-sens analysis in the study showing 
increased expression of CD63 with increased allergen concentrations up to maximum CD63 up-regulation. 
Paper I-II: CD-sens to peanut and Ara h 2 were analyzed in all 38 children who 
participated in study population 1. 
Paper III: CD-sens peanut and Ara h 8 were analyzed in the girl who participated 
in the case report.  
Paper V: CD-sens to peanut, Ara h 8 and Gly m 4 were analyzed in all 20 
children who participated in study population 2. 
50% of maximum
CD63 up-regulation
Peanut (ng/ml)
LC50
Maximum CD63 
up-regulation (100%)
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4.3 ORAL PEANUT CHALLENGES 
The children had to be healthy at time of the challenge and no challenge was 
performed if the child had an on-going infection or an allergic reaction to other 
food or inhalant allergens. The challenge was also postponed if the child had 
used antihistamine less than four days or steroids less than two weeks prior to the 
challenge. Before challenge, medical treatment was prepared and a peripheral 
venous catheter was provided after local anesthesia (EMLA®). 
Study population 1 (Paper I-III, IV) 
A DBPCFC to peanut was performed, followed by a SBFC to peanut. The study 
design is shown in Figure 9. All three challenges were planned to be performed 
within a month and at least one week was allowed to go by between the 
challenges to avoid carry-over effects. For ethical reasons, children did not 
perform the SBFC if they had a very severe reaction and/or experienced a lot of 
discomfort at the DBPCFC. All challenges were performed using a validated 
recipe for peanut challenge medium (chocolate balls) containing 11% roasted 
peanuts and 7% fat (128). The challenge medium was given in increasing doses 
in 5 steps from 1 mg to 5 g (1 mg, 10 mg, 100 mg, 1 g and 5 g) every 30 
minutes; 6.1 g is equivalent to approximately 8-9 whole roasted peanuts. A 
positive test was defined by objective symptoms and the severity of the reaction 
was graded from 1 to 5 according to Astier et al. (129) as shown in Table 3.  
Table 3. Severity scoring according to Astier (129). 
 
Symptom 
score 
Symptoms 
0 no symptoms 
1 abdominal pain that resolved without medical treatment, rhinoconjunctivitis or 
urticaria <10 papules, rash 
2 one organ involved 
*abdominal pain requiring treatment  
*generalized urticaria  
*non laryngeal angioedema 
*mild asthma (cough, fall of peak expiratory flow <20%) 
3 two organs involved (of symptoms mentioned under 2) 
4 three organs involved (of symptoms mentioned under 2) or asthma requiring 
treatment or laryngeal edema, or hypotension 
5 cardiac and respiratory symptoms requiring hospitalization in the intensive care 
unit 
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A negative test was defined as no objective allergic symptoms within two hours 
after the challenge was completed. 
A dietitian without knowledge of the study subjects prepared the challenge 
medium (chocolate balls) -two with peanut (active) and one without peanut 
(placebo) for every study subject. The chocolate balls were labeled, with the 
patient number and in random A and B for each patient, stored in a fridge and 
taken out in random order before each challenge. The third chocolate ball labeled 
C was always active and was used for the SBFC. The random code was 
concealed to the study subject, parents, nurses and the doctor during the two first 
challenges. The third challenge, when performed, was always done with a 
chocolate ball containing peanuts. This was known to the doctor and the nurses 
performing the challenges but not to the child or the parents. 
Study population 2 (Paper IV-V) 
An OFC to peanut was performed in all children. If an objective reaction 
occurred during the OFC, a DBPCFC was planned. The study design is shown in 
Figure 10. 
The OFC was performed outside the pollen season; pure roasted peanut was 
given every 20 minutes in four steps from 100 mg to 5 g (100 mg, 1 g, 5 g and an 
additional 5 g). The total amount of peanut, 11.1 g corresponds to approximately 
15-16 whole roasted peanuts. A negative challenge was defined as no objective 
allergic symptoms during the first hour after the challenge was completed. OAS, 
i.e. local symptoms from the oral cavity without symptoms from the skin, 
gastrointestinal tract, breathing difficulties or tissue swelling (68), was regarded 
as a negative outcome if the symptoms disappeared spontaneously without 
medication. A challenge was defined as positive if objective symptoms from the 
skin, gastrointestinal tract, respiratory tract and/or cardiovascular system 
occurred.  
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4.1 STATISTICAL ANALYSIS 
The statistical analyses were performed using IBM SPSS v20.0, v22.0 (Chicago, 
IL, USA) and SAS v9.1 (SAS Institute Inc., Cary, NC, USA). The distributions 
of the variables from the two study populations were not normal distributed. 
Apart from skewed distributions there were values outside the measuring ranges 
and scores measured on ordinal scale. Therefore non-parametric statistical 
methods were used. No adjustment for multiple testing has been performed. 
Thus, significant results should be regarded as descriptive and explorative. 
4.1.1 Wilcoxon rank-sum test (I, IV, V) 
In paper I and IV Wilcoxon rank sum test was used to compare differences in 
IgE-ab, IgG4-ab, CD-sens, eliciting dose and severity scoring in study subjects 
positive or negative in peanut challenges. In Paper V the same test was used to 
assess differences of CD-sens and IgE-ab in children with or without OAS.  
4.1.2 Spearman rank-order correlation (I, II, IV)  
Spearman rank-order correlation (rs) was used to assess the relation between the 
cumulative amount of peanut tolerated before reaction at challenge and the 
severity of the reaction, in paper I. Correlations between the first and second 
value of severity score, eliciting dose and CD-sens were also estimated with 
Spearman rank-order correlation in Paper II. In Paper IV correlations were 
calculated between IgE-ab, IgG4-ab and the ratio of IgE/IgG4-ab. 
4.1.3 Wilcoxon signed-rank test (II) 
Wilcoxon signed-rank test was used to test differences between the first and the 
second challenge for severity score, eliciting dose and CD-sens value in study 
subjects who reacted to both active challenges. The value for eliciting dose and 
the CD-sens value was tested on log-transformed values, thus testing the relative 
change. 
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4.1.4 Bland-Altman plot (II) 
Bland-Altman plots were used to present the differences in severity score, 
eliciting dose and CD-sens value from the first and second active challenge in 
Paper II. 
4.2 ETHICAL APPROVAL  
The studies in the thesis were approved Regional Ethical Review Board at 
Karolinska Institutet in Stockholm, Sweden. (Identification number 2008-1001-
31/2 and 2010/133-31/3). Written informed consent was obtained from all study 
subjects and their parents before the children were included in the study. 
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5 RESULTS 
5.1 PAPER I 
Paper I demonstrates that CD-sens and CRD are useful tools for diagnosis of 
peanut allergy.  
5.1.1 DBPCFC to peanut 
Thirty-eight children were evaluated and no child reacted to placebo. Twenty-
five children (66%) reacted at challenge while thirteen children (34%) passed 
without any objective symptoms. Ten children with a positive and eight with a 
negative peanut challenge claimed they had never eaten peanuts. Five children 
with negative challenges reported previous allergic reactions to peanut. The 
symptoms were scored according to Astier et al (129), shown in Table 3, and the 
severity of the reaction was mild to moderate (Grade 1-3) in fifteen children 
(60%). Nine children (36%) had severe reactions and one child (4%) was sent to 
the intensive care unit for observation (Grade 5) (Figure 13). 
  
Figure 13. Severity score and eliciting dose in children positive in challenge from study population 1. 
There was no association between the eliciting dose of peanut at the challenge 
and the severity of the reactions (rs=0.21, p=0.32), which means that some 
children reacted to low doses with severe symptoms while other children were 
able to eat more peanut without severe symptoms.  
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5.1.2 CD-sens to peanut and Ara h 2 
 Ninety-two percent (22 /24) of the children with a positive DBPCFC were 
positive in CD-sens to peanut and ninety-two percent (23/25) were positive to 
Ara h 2. Two children were classified as low responders, having too weak 
response to the positive control, anti-FcεRI (<16%) to allow further evaluation. 
Of the thirteen children with a negative DBPCFC 77% (10/13) were negative in 
CD-sens after stimulation with peanut and Ara h 2 as shown in Figure 14.  
 
 
Figure 14. CD-sens to peanut in children with a positive (○) or negative (□) DBPCFC.  
Horizontal bars, median. 
Three children negative in challenge had positive values in CD-sens to peanut 
and Ara h 2. All of these three had low concentrations of IgE-ab to Ara h 2 (0.2, 
0.9 and 1.9 kUA/L). However, all children negative in CD-sens to peanut were 
negative in DBPCFC as shown in Figure 14. Children with a positive DBPCFC 
had significantly higher levels of peanut CD-sens, [1.3 (range 0.4-29.3)] than 
children with negative DBPCFC [0 (range 0-0.5)] (p<0.0001). The value for CD-
sens to Ara h 2 differed also significantly between children positive, 84.5 (range 
9.0-385.0) and negative 0 (range 0-33.2) in DBPCFC (p<0.0001). One child was 
positive in CD-sens but the CD63 expression barely reached the 5% cut off, 
therefore a CD-sens value could not be calculated.  
CD-
sens
Postivie
DBPCFC 
Negative 
DBPCFC
Peanut Total 241 (65%) 13 (35%)
Negative 0 (0%) 10 (77%)
Positive 222 (92%) 3 (23%)
Low responders 2 (8%)
Ara h 2 Total 25 (66%) 13 (34%)
Negative 0 (0%) 10 (77%)
Positive 232 (92%) 3 (23%)
Low responders 2 (8%)
1 One child was not tested in CD-sens (peanut).
2 One child was positive in CD-sens but the CD63 expression barely 
reached the cut off, hence a CD-sens value could not numerically be 
calculated0.01
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1
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Peanut Ara h 2
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D
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5.1.3 IgE-ab to peanut and peanut components  
Children with a positive DBPCFC had significantly higher median 
concentrations of IgE-ab to peanut, Ara h 1, Ara h 2 and Ara h 3 compared to 
those negative at the challenge (p<0.0001 for all). No significant differences 
were found for the median concentrations of IgE-ab to Ara h 8 and Ara h 9 
between children positive vs. negative in DBPCFC (Figure 15). Two children 
positive in DBPCFC had low IgE-ab concentrations (0.6 and <0.1 kUA/L) to Ara 
h 2. Three children negative in DBPCFC had IgE-ab to Ara h 2 (0.2; 0.9; 1.9 
kUA/L). 
 
Figure 15. IgE-ab to peanut and peanut components in children with a positive (○) or negative (□) 
DBPCFC. Horizontal bars = median, ns= not significant 
 
The IgE-ab fraction was calculated and children positive in DBPCFC had a 
median IgE-ab fraction of 26% (range 1-72%) for peanut and 11% (range 0-
55%) for Ara h 2, while those negative in DBPCFC had 0% (range 0-10%) and 0 
% (range 0-2%) p<0.0001 for both. 
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5.1.4 Accuracy of peanut allergy diagnosis 
All children in study population 1 had a suspected peanut allergy and had 
previously been recommended by their doctor to avoid peanuts. Of the 38 
children included, 53% (20/38) had a convincing history of peanut allergy. 
However, 47% (18/38) children had been diagnosed via laboratory result 
showing IgE-sensitization to peanut although they claimed that they had never 
eaten peanuts. Forty percent (10/25) of peanut allergic children (positive in 
peanut challenge) and sixty-two percent (8/13) of the tolerant children (negative 
in challenge) had been diagnosed by clinical work-up without a previous 
reaction. Adrenaline auto-injector had been prescribed before challenge to 76% 
(19/25) of the children positive and 85% (11/13) of the children negative in 
challenge (Figure 16). 
 
Figure 16.  
A. History of clinical reaction at inclusion and reaction in DBPCFC.  
B. Prescribed adrenaline auto-injector before inclusion in the study. 
 
A
B
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5.2 PAPER II 
Paper II concludes that the reproducibility of a positive or negative test result is 
100% for both CD-sens and peanut challenge. However, severity score and 
eliciting dose were not reproducible for oral peanut challenges when the 
challenge was repeated. 
5.2.1 Reproducibility of oral peanut challenges 
Of the 38 children in study population 1, 27 were performing three challenges 
(two active and one placebo). Eleven children were excluded since they reacted 
severely or experienced a lot of discomfort at the first DBPCFC. Fourteen 
children (52%) reacted at both peanut challenges, but not to placebo and were 
considered allergic to peanut. The severity of the challenge reactions was scored 
and the eliciting doses were determined in every patient. Three children (J28, 
J36, J41) reacted at the same severity score and had the same eliciting dose at the 
two peanut challenges. All other children (n=11) scored differently or reacted at 
different eliciting doses. (Figure 17 and Table 4). 
 
Figure 17. Eliciting dose and severity scoring in the same peanut allergic child at the two peanut 
challenges. The amount of peanut was the same for each child at the five dose steps: 
 Dose 1=0.01 g; Dose 2 = 0.01 g; Dose 3=0.1 g; Dose 4=1 g; Dose 5=3.6-5 g 
 
 
  
  
38 
 
Table 4. Age, sex and challenge outcome in peanut allergic children. 
 
 
 
Thirteen children (48%) did not react at any of the three challenges. All children 
negative at the challenges consumed full doses (6.1 g peanut). In children with a 
positive challenge the arithmetic mean of difference in the severity scores 
(challenge 2 - challenge 1) was 0.143 (p=ns) and the geometric mean of the ratio 
of the doses (challenge 2/challenge 1) was 1.834 (p=ns). No association was 
 
 1st peanut challenge 2nd peanut challenge 
Patient  sex Age 
(years) 
Symptoms Severity 
score 
peanut (g) Symptoms Severity 
score 
Peanut (g) 
J2   
 
female 12.7 urticaria,  
stomach-ache 
mouth-itch 
tierdness 
3 1.1 asthma, skin-itch, 
rhinitis, urticaria, 
stomach-ache 
4 6.1 
J8    
 
male 15.4 stomach-ache 
mouth-itch 
2 0.1 conjunctivitis, 
rhinitis,       
stomach-ache 
2 1.1 
J15  
 
female 17.4 stomach-ache, 
mouth-itch 
2 0.1 mouth-itch, 
stomach-ache, 
urticaria, rhinitis 
3 1.1 
J17   
 
female 14.0 tiredness,    
mild asthma, 
mouth-itch 
4 6.1 tiredness, stomach-
ache, vomiting, 
conjunctivitis 
2 6.1 
J19   
 
male 9.8 mouth-itch 1 0.01 mouth-itch, 
stomach-ache 
1 3.6 
J22 
 
male 5.4 stomach-ache 1 4.1 conjunctivitis, 
stomach-ache, 
tiredness 
2 6.1 
J24 
 
female 17.6 tiredness, 
vomiting, 
mouth- itch,  
stomach-ache 
urticaria 
3 6.1 mouth-itch 1 1.1 
J28 
 
male 7.6 stomach-ache 1 6.1 erythema, 
 stomach-ache, 
tiredness 
1 6.1 
J31   
 
male 19.0 mouth-itch, 
urticaria, cough, 
stomach-ache, 
tiredness, 
erythema 
4 1.1 mouth-itch 1 0.01 
J33 
 
female 12.2 mouth-itch 
tiredness, 
stomach-ache 
1 6.1 stomach-ache, 
tiredness 
2 0.1 
J36   
 
male 18.4 mouth-itch, 
stomach-ache, 
tiredness 
2 0.001 mouth-itch, 
stomach-ache 
2 0.001 
J38 
 
female 7.9 cough, tiredness 2 0.01 hoarseness, cough, 
mouth-itch, 
conjunctivitis, 
rhinitis, vomiting, 
stomach-ache, 
tiredness, urticaria 
4 6.1 
J39   
 
male 5.9 mouth-itch , 
stomach-ache 
tiredness 
2 1.1 mouth-itch, asthma 4 1.1 
J41   
 
female 11.8 mouth-itch, 
stomach-ache, 
tiredness 
2 0.1 mouth-itch, 
stomach-ache, 
tiredness 
2 0.1 
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obtained between the first and second challenge regarding severity score 
(rs=0.11; p=ns) and eliciting dose (rs=0.35; p=ns). 
5.2.2 Reproducibility of CD-sens to peanut 
CD-sens was performed with blood drawn before the first and second challenges 
in all children (n=26) except one. In this child, blood was collected at the second 
and third challenges due to a misunderstanding. All children with a positive CD-
sens at the first challenge were also CD-sens positive at the second challenge. 
Twelve of fourteen children with a positive challenge were also positive in CD-
sens to peanut (Figure 18). The remaining two could not be evaluated since they 
were low responders i.e. had too weak response to the positive control anti-
FcεRI (<16%). Three children had slightly positive values in CD-sens (0.3-0.5) 
but were negative in challenge. However, all ten children negative in CD-sens 
were also negative at both peanut challenges. The geometric mean of the ratio of 
CD-sens values (challenge 2 /challenge 1) in children with a positive challenge 
was 1.035 (p=ns) and the association between the two CD-sens values was 
strong (rs=0.94, P<0.001). 
 
Figure 18. CD-sens to peanut in the same peanut allergic child before the two first challenges. 
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5.3 PAPER III 
Paper III and V show that CD-sens to Ara h 8 is positive in a majority of the 
children IgE-sensitized to birch and Ara h 8 and indicate that IgE-sensitized 
basophils can be activated by an intact Ara h 8 allergen and initiate allergic 
inflammation.  
5.3.1 Birch pollen allergy and cross-sensitization to peanut 
Paper III is a case report describing a 16-year-old girl with rhinoconjunctivitis 
during birch pollen season, who also experiences OAS when eating some fruits. 
She passed two oral peanut challenges (study population 1) and started to eat 
peanuts at home without objective symptoms. However, on one occasion she ate 
a large amount of peanuts (approximately 300 g), developed a severe allergic 
reaction and needed acute medical treatment.  
At time of challenge she had IgE-ab to peanut and Ara h 8 but not to Ara h 1, 
Ara h 2 or Ara h 3. CD-sens to peanut was also negative. After the acute reaction 
when eating 300 g of peanuts she was re-evaluated for a suspected peanut 
allergy. Interestingly, the IgE-ab pattern to the various peanut allergen 
components was unchanged, which was also the case when the analyses were 
repeated in 2013. CD-sens was also 
re-analyzed in 2013, and was still 
zero to peanut but positive to 
Ara h 8, as shown in Table 5. The 
girl is still eating peanuts, 
approximately a handful at a time 
(~ 40 g), but avoids larger amounts.  
 
2008 2011 2013
IgE# 297 n.t. n.t.
IgE-ab Bet v 1* 22 n.t. n.t.
IgE-ab peanut* 1.0 2.4 1.1
IgE-ab Ara h 1* <0.1 <0.1 <0.1
IgE-ab Ara h 2* <0.1 <0.1 <0.1
IgE-ab Ara h 3* <0.1 <0.1 <0.1
IgE-ab Ara h 6* <0.1 <0.1 n.t.
IgE-ab Ara h 8* 39.1 12.0 12.7
IgE-ab Ara h 9* <0.1 <0.1 <0.1
CD-sens peanut 0 n.t. 0
CD-sens Ara h 8 n.t. n.t. 12.5
Table 5. Immunological analysis. 
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5.4 PAPER IV 
Paper IV shows that tolerant children with peanut sensitization are characterized 
by low levels of IgG4-ab to peanut and Ara h 2 but relatively high IgG4/IgE- 
antibody ratios. 
5.4.1 IgG4-antibodies and oral peanut challenges  
Children from both study populations were included (study population 1 and 2). 
Of 58 investigated patients 25 were considered as positive (allergic) at the 
challenge and 33 as negative (tolerant).  
Allergic children had low levels of IgG4-ab to peanut [median: 0.28 (range: 
<0.07-10.7) mg/L] and Ara h 2 [0.15 (<0.07-2.3) mg/L] but nonetheless levels 
significantly higher than those in tolerant children [peanut: 0.14 (<0.07-0.83) 
mg/L and Ara h 2: <0.07 (<0.07-0.62) mg/L] p<0.05 and p<0.001, respectively. 
However, tolerant children had higher concentrations of IgG4-ab to Ara h 8 
[<0.07 (<0.07-2.2) mg/L] than allergic children [<0.07 (<0.07-0.56) mg/L; 
p<0.05)] (Figure 19). The median levels of IgG4-ab to Ara h 1 and Ara h 3 in 
tolerant children were <0.07 (<0.07-0.1) mg/L and <0.07 (<0.07-0.9) mg/L, 
respectively and in allergic children <0.07 (<0.07-0.37) mg/L and <0.07 (<0.07-
0.35) mg/L, respectively. Statistical analyses to compare differences in Ara h 1 
and 3 were not done, since most IgG4-ab concentrations were below LLOQ in 
both allergic and tolerant children.  
Significant correlations were found between concentrations of IgE-ab and  
IgG4-ab to Ara h 2 and peanut in the allergic children (rs=0.54; p<0.01 and 
rs=0.44; p<0.05, respectively) but not for the other components or for the tolerant 
children. The peanut- and Ara h 2 IgG4/IgE-antibody ratios in peanut tolerant 
individuals were significantly higher than in the allergic children (p<0.05 and 
p<0.001, respectively) (Figure 19). Most of the tolerant children had very low or 
undetectable IgG4- or IgE-ab levels to Ara h 1 and 3, precluding antibody ratio 
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calculations. There was no significant difference in the Ara h 8 IgG4-/IgE-ab 
ratio between allergic and tolerant children. 
  
 
Figure 19. IgG4-ab and IgG4-ab /IgE-ab ratio to peanut and peanut components in children positive (o) or 
negative (□) in challenge. Median and interquartile range is included in the figure. 
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5.5 PAPER V 
In paper V, none of the children sensitized to Ara h 8 but not to Ara h 1, Ara h 2 
or Ara h 3, had a systemic allergic reaction at the challenge. However, the 
majority of children (85%) were positive in CD-sens to Ara h 8, indicating that 
they had Ara h 8 IgE-ab sensitized basophils which could be activated by intact 
Ara h 8 proteins and initiate an allergic inflammation. 
5.5.1 CD-sens, Ara h 8 and oral peanut challenges 
IgE-ab 
At the time of challenge, all children had IgE-ab (>0.1 kAU/L) to peanut and Ara 
h 8. The median (range) for peanut was 0.7 (0.1-16.1) kUA/L, for Ara h 8, 6.4 
(0.5-131.7) kUA/L and for Bet v 1 30.1 (1.5-202.6) kUA/L. Three children had 
low levels of IgE-ab to Ara h 2 (0.2-0.4) kUA/L. All children but one had IgE-ab 
to Gly m 4 with a median of 4.9 (1.5-18.9) kUA/L. There was no significant 
difference in IgE-ab levels to peanut (p=0.93) or Ara h 8 (p=0.93) in children 
with or without OAS at the challenge. 
CD-sens 
All children but one (Patient 4) were negative in CD-sens to peanut. This child 
had IgE-ab to Ara h 2 (0.4 kUA/L) at the time of challenge, but not at inclusion. 
Seventeen children (85%) were positive in CD-sens to Ara h 8. At time of the 
challenge the median of CD-sens to Ara h 8 was 5.9 (0-82.8). Concentrations of 
IgE-ab to Ara h 8 in the three children with negative CD-sens to Ara h 8 were 
0.5, 0.8 and 6.3 kUA/L and the corresponding IgE-ab fraction size to Ara h 8 was 
0.03%, 0.04% and 4.9%, respectively (Table 6). 
There were no significant difference in CD-sens to Ara h 8 (p=0.42) between 
children with (n=5) and without (n=15) OAS at the peanut challenge.  
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Table 6. Immunological analysis and symptoms at challenge 
 
OAS = Oral allergy syndrome 
*kU/L 
**kUA/L 
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6 DISCUSSION 
This thesis focuses on peanut allergy and the aim was to evaluate clinical and 
immunological characteristics through peanut challenges, CRD and CD-sens in 
children IgE-sensitized to peanut with a suspected peanut allergy.  
6.1 ORAL PEANUT CHALLENGES 
The main goal of a peanut challenge is to determine, under safe conditions, if a 
patient is allergic or not. However, severe reactions do happen (130), and even 
though DBPCFC is the gold standard for peanut allergy diagnosis, (99-103) 
reactions to placebo also occur (131) and have been reported in significant 
numbers (132, 133). Furthermore, performing DBPCFC is also difficult and the 
procedure posses a number of practical problems and the method has several 
pitfalls (134, 135). 
In our study no child reacted to placebo and all the children who were positive in 
the first active challenge were also positive in the second active challenge, 
indicating that peanut challenge is reproducible for a positive or negative 
challenge outcome.  
Several factors affect the outcome of a peanut challenge in addition to the 
amount of allergen given during challenge, for example gastric or respiratory 
infections, hormonal factors (menstruation), psychogenic factors (stress) and 
drugs (e.g. antihistamine, corticosteroids) (28, 136). A recently published study 
investigating challenge outcome in peanut allergic individuals could not find any 
consistent relationships between the severity of challenge outcome and the 
cumulative dose given (130). This is in line with the results of Paper I, showing 
that 66% of the children reacted to the peanut challenge but we were not able to 
see any association between the severity of the reaction and the amount of 
peanut eaten.  
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Several studies have also tried to determine risk factors and eliciting dose in 
peanut allergic patients to predict the clinical sensitivity (137-140). Skripak and 
colleagues evaluated the effect of 23 weeks of oral immunotherapy with milk by 
using DBPCFC before and after treatment (141). The outcome of the food 
challenge was based on the lowest dose that caused a reaction and not on 
changes in the severity of the reactions. In that study 29% of the patients in the 
placebo group (n=7) did not react at the same dose when the DBPCFC was 
repeated (141). Van der Zee and colleagues aimed to evaluate if presence of risk 
factors for a severe peanut allergy is associated with the patient’s clinical 
sensitivity. To do this they determined the eliciting dose of peanut in a DBPCFC 
and examined whether this would predict the severity of the allergic reaction. 
However, they were not able to find a relation between the eliciting dose in 
DBPCFC and the severity of a reaction at home (137). This is in line with our 
results showing that the severity score and the eliciting dose were not 
reproducible in a repeated oral challenge and may indicate that a child with a 
mild reaction could react severely on renewed exposure to peanuts or vice versa. 
A positive food challenge reaction should always be based on objective 
symptoms (99-103, 142). For ethical reasons it is not always possible to provoke 
objective symptoms in all patients, which is a problem when evaluating 
challenge outcome (136). This could also be demonstrated in Paper II. One girl 
(J33) experienced symptoms from the mouth cavity (6.1 g) at the first challenge 
but no medical treatment was needed. A few hours later she suffered a late 
reaction with severe stomach ache and fell asleep. At the second active challenge 
she reacted to a low dose (0.1 g) with severe stomach ache that required medical 
treatment and the challenge were stopped. Another child (J36) refused to eat 
more than the first dose (1 mg) because of mouth itch and stomach pain that 
resolved after medication at both active challenges. He passed the placebo 
challenge without any symptoms.  
There are several guidelines for how to perform a DBPCFC (99, 100, 102, 103, 
142). However, different research groups still use their own challenge schedules 
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and severity symptom scores (63, 129, 137, 140, 143-145). In 2012 a new 
consensus report for standardization of DBPCFC was published with practical 
recommendations for both challenge schedules and severity scoring, which 
hopefully will contribute to harmonizing the challenge procedure (101). 
Unfortunately, there is still no objective measurement combining both severity 
of the reaction and amount of peanut eaten at the challenge.  
6.2 COMPONENT RESOLVED DIAGNOSTICS 
There has been intense research worldwide concerning peanut allergy during the 
last decade. In the beginning of 2007, when our studies were planned, CRD was 
not yet in clinical use. Sensitization and the clinical importance of different 
peanut allergens were widely discussed. More research was needed investigating 
peanut components in relation to the gold standard, DBPCFC. 
Peanut storage proteins 
We found in Paper I that the IgE-ab levels to the storage proteins Ara h 1, Ara h 
2, and Ara h 3 are significantly increased in children positive in DBPCFC to 
peanut compared to those negative in challenge. This result is in line with other 
reports investigating peanut allergy in relation storage proteins and Ara h 2 
seems to be the most important allergen (111-113, 146-148). However, lack of 
IgE-ab to Ara h 2 does not exclude a peanut allergy and sensitization patterns 
vary in different regions worldwide (113, 149). 
In Paper I, five patients negative at the peanut challenge had IgE-ab to the 
storage proteins (>0.1 kUA/L). Three had IgE-ab to Ara h 2 (>0.1 - <2.0 kUA/L), 
one child had IgE-ab Ara h 3 (5.8 kUA/L) and the fifth child had IgE-ab to Ara h 
1 and Ara h 3 (14.1 and 0.8 kUA/L, respectively). Elevated levels of Ara h 2 in 
peanut tolerant children have also been observed by others (150). Cross-
reactivity between the peanut and tree nut allergens has been described (105, 
151) and could be a speculative explanation for the elevated levels of IgE-ab to 
the peanut storage proteins. However, the three children with IgE-ab to Ara h 2 
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but negative in challenge were also weakly positive in CD-sens to peanut, which 
may be a sign of developing tolerance or a developing peanut allergy. Of the 
children positive in challenge, all but one were positive for IgE-ab to Ara h 2. 
This child was negative in all components including IgE-ab to Ara h 2 but 
positive in IgE-ab to peanut. Unfortunately this child was a low responder in 
CD-sens and could not be evaluated.  
There is currently no treatment for peanut allergy except avoidance. However, 
anti-IgE-ab treatment may be useful therapy in the future. An earlier study has 
shown that a small IgE-ab fraction, <1% clinically relevant IgE-ab of IgE, is 
important for successful anti-IgE treatment (152). In our study, the IgE-ab 
fraction differs significantly between children positive and negative in DBPCFC. 
Children positive in DBPCFC had significantly larger IgE-ab fractions (25% to 
peanut and 11% to Ara h 2) than those who were negative. This suggests that the 
fraction size should be considered before starting treatment with anti-IgE in 
patients with food allergy. 
6.3 CD-SENS 
Peanut and Ara h 2 
In Paper I we concluded that peanut allergic children have significantly higher 
levels of CD-sens to peanut compared to tolerant children. CD-sens has earlier 
been shown to correlate with asthma sensitivity in both stable and instable 
asthma (16, 17). Recently published studies investigating tolerance to cow milk 
showed that children with a severe milk allergy had more activated basophils 
than children who tolerated milk. It was also possible to discriminate between 
children who tolerated heated milk and those who did not (153, 154). This is in 
line with our study showing that children who tolerated peanuts were negative in 
CD-sens to peanut. These investigations may indicate that CD-sens can signal 
presence or absence of tolerance and when CD-sens is negative the probability 
for an allergic reaction is low. 
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A recent published study investigating peanut allergic children and severity of 
the allergic reaction after accidental ingestion of peanut showed that children 
with anaphylaxis had significant higher levels of CD-sens to peanut than 
children without anaphylaxis (155). Paper II was planned to investigate the 
severity of the outcome of peanut challenge and compare the results to peanut 
CD-sens. This aim could not be achieved: the eliciting dose and symptoms 
differed when the peanut challenge was repeated, making it impossible to 
quantitatively estimate the severity of a peanut allergy on the basis of an oral 
food challenge. However, the reproducibility of a negative or positive test was 
100% for both challenge and CD-sens to peanut and Ara h 2. 
The correlation between the two CD-sens values was strong. A good correlation 
does not always mean a high reproducibility, but with a high reproducibility 
there should be a good correlation. For the peanut challenge we could not 
demonstrate any statistically significant differences or correlations for doses or 
symptoms between the two challenges. Thus the low correlation supports that the 
reproducibility of peanut challenge was poor for eliciting dose and severity 
score. This is in contrast to CD-sens, where we did not find any significant 
differences but a significant and strong correlation between the two occasions, 
supporting that CD-sens results are strongly associated with each other.  
We did not find any non-responders to CD-sens, which was surprising since 10-
20% of the population has been reported to have non-responding basophils on 
activation (123), i.e. negative to the positive control (anti-FcεRI). However, in 
our experience the figure is 5-10% (124). Two children in our study with a 
positive DBPCFC had basophils with a weak response, <16%, to anti-FcεRI, 
“low responders”. Thus, in patients with a convincing history of a peanut allergy 
who are non- or low responders in CD-sens, an oral peanut challenge must be 
recommended. 
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Ninety-two percent of the children with a positive DBPCFC had a positive CD-
sens to peanut and Ara h 2, and if the low responders were excluded, the 
concordance with a positive CD-sens was hundred percent. 
All children positive in CD-sens to peanut were also positive in CD-sens to Ara 
h 2. One benefit of using a recombinant allergen like Ara h 2 is that the exact 
protein content is known. However, pure proteins can sometimes be difficult to 
handle because of solubility issues and the extremely low concentrations needed. 
The advantage of using a crude peanut extract is that the same raw material can 
be used for both CD-sens stimulation and DBPCFC. However, as for other tests 
using allergen extract, the CD-sens value completely depends on the 
concentration and the purity of the allergen extract. It is not possible to compare 
extracts of different allergens, as they are not standardized.  
There is a considerable variation in the performance in flow cytometry assays 
(119) and the European Interest Group for evaluation of BAT in clinical use 
(EuroBAT) is working on a harmonized protocol to make results from different 
international laboratories comparable (119).  
PR-10 proteins 
Ara h 8 belongs to the PR-10 protein family and is a homolog of the major 
allergen in birch pollen (Bet v 1) (105). Sensitization to birch pollen can lead to 
development of IgE-ab to PR-10 proteins in fruits and vegetables, such as soy 
(Gly m 4) (156, 157) and hazelnut (Cor a 1) (158-160). Children sensitized to 
Ara h 8 but not to the storage proteins mostly tolerate peanuts (126) whereas 
severe reactions have been reported in children with isolated Gly m 4 
sensitization (156, 161, 162). The amount of Ara h 8 in peanut is very low and it 
is also known to have a low stability to heat and gastric degradation (163), which 
could be a plausible explanation for why children with isolated Ara h 8 
sensitization tolerate small amounts of peanut (126). However, a recent study 
reported that in 1 g roasted peanuts, Ara h 8 represent 8 μg (0.8%) and that     
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Ara h 8 has some proteolytic stability to gastric and pancreatic degradation, in 
vitro (164).  
In paper V, we were able to show that the majority of children with an isolated 
Ara h 8 sensitization were positive in CD-sens to Ara h 8. This indicates that Ara 
h 8 has the ability to initiate an allergic inflammation if basophils IgE-sensitized 
to Ara h 8 become activated by an intact Ara h 8 allergen. The ability of Ara h 8 
to cause an allergic inflammation has been shown by others (163). These 
findings could be a plausible explanation for why the girl with birch pollen 
allergy and mono sensitization to Ara h 8 in our case report (Paper III) tolerated 
small amounts (<40 g) of peanut but had a severe reaction after eating a large 
amount (approximately 300 grams). This observation might indicate that birch-
pollen allergic children with cross-sensitization to peanut can tolerate eating 
some peanuts but need to be careful with larger amounts of peanuts. 
We also investigated CD-sens to Gly m 4, in order to compare it with CD-sens to 
Ara h 8. Previous reports have shown that among birch pollen-allergic 
individuals, those who are also IgE-sensitized to Gly m 4 report more severe 
symptoms after drinking soy milk during birch pollen season than those who are 
sensitized to Ara h 8 who have eaten peanuts (126, 162, 165). The children in 
our study were selected for having IgE-ab to Ara h 8, but 19/20 also had IgE-ab 
to Gly m 4. However, only 11 were CD-sens positive to Gly m 4. We did not 
perform soy challenges but it would be of great interest to investigate if the 
children with positive CD-sens to Gly m 4 would react at an oral challenge to 
soy.  
6.4 IgG4-ANTIBODIES 
In Paper IV we investigated the levels of IgG4-ab to peanut and peanut 
components in comparison to DBPCFC. It has been reported that measurement 
of IgG4-ab cannot be used to determine if a patient is peanut allergic or not (150, 
166, 167) and that IgG4-ab only seem to be part of a physiological response after 
prolonged antigen exposure (168). IgG4-ab concentrations in our study to peanut 
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and Ara h 2 were low but significantly higher in children with peanut allergy. 
However, tolerant children had significantly higher ratios of IgG4-ab/IgE-ab to 
peanut compared to allergic children. This could indicate a protective role for 
IgG4-ab against allergic reactions. IgG4-ab can bind to mast cells and basophils 
via the FcγRIIB receptor. Cross-linking between the IgE/FcεRI and 
IgG4/FcγRIIB complexes by allergens inhibits the IgE-mediated cell-
degranulation (54, 55). IgG4-ab may also act as blocking antibodies by 
interfering with the binding between allergen and IgE antibodies (169, 170). 
It has previously been reported that IgG4-ab correlate with IgE-ab levels to 
peanut and peanut components especially in children avoiding peanuts (171). A 
similar observation was done in the present study using peanut challenges and 
the correlation could be due to that both IgE-ab and IgG4-ab production is 
dependent on Th2-type cytokine synthesis (51).  
All children in this study avoided peanuts thus the levels of IgG4-ab was not 
depended on the amount of peanut eaten before the challenge. This could 
indicate that the IgG4-ab levels could be associated with peanut allergy and not 
only to allergen exposure (172).  
Hong et al. previously published that IgG4-ab to peanut and its components were 
not helpful when investigating the severity of peanut allergy since they did not 
find any differences between allergic and tolerant children (167). I our study 
there were a significant difference in IgG4-ab between allergic and tolerant 
children but the range of the IgG4-ab levels was too wide to allow the IgG4-ab to 
be used as reliable diagnostic markers. 
The role of IgG4-ab has also been investigated, in other studies, in birch-allergic 
individuals where a high ratio of IgG4-/IgE-ab to the PR-10 allergen in hazelnut 
(Cor a 1) or apple (Mal d 1) correlated with tolerance (173). However, there was 
a high individual variability between patients; hence no recommendation using 
the antibody ratio in the prognosis of birch-related food allergy was made. In our 
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study we did not find any differences in the IgG4-/IgE-ab ratio to the PR-10 
allergen Ara h 8 between allergic and tolerant children.  
6.5 ACCURACY OF PEANUT ALLERGY DIAGNOSIS 
A diagnosis of peanut allergy has a great impact on a patient’s quality of life. It 
necessitates a strict diet; the patient must avoid foods containing peanuts because 
accidental ingestion may result in anaphylactic reactions, which can be fatal (2-
4). Prescription of adrenaline auto-injectors is common because no diagnostic 
method is available to predict the severity of a peanut allergy. All the fear and 
worry related to the threat of an anaphylactic reaction also impairs quality of life 
(9-11) and therefore an accurate diagnosis is highly important to avoid serious 
consequences for the children and their families. 
In our first study (study population 1) all 38 children had a suspected peanut 
allergy and they had been recommended to avoid peanuts before inclusion in the 
study. Eight of the thirteen children (62%) avoided peanuts before challenge due 
to peanut IgE-sensitization and eleven children (85%) had been prescribed an 
adrenaline auto-injector. On the other hand of twenty-five children positive in 
challenge six of them (24%) had not an auto-injector prescribed. This indicates 
how difficult it is to diagnose peanut allergy properly. It is also important to 
avoid screening for peanut allergy without strong clinical suspicion of a clinical 
reaction to peanut. However, with new diagnostic opportunities like the CRD 
and CD-sens, the accuracy of peanut diagnoses will improve.  
6.6 STRENGTHS AND LIMITATIONS 
6.6.1 Study design 
The strength of our study design was that all children were sensitized to peanut 
and had a diet without peanuts. All children were also orally challenged, which is 
a strength since many other studies rely on results of previous documented 
reactions. Besides, the challenges were done in the same hospital, Sach’s 
Children and Youth Hospital, where the personnel at the Allergy department 
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have long experience of performing food challenges. Limitations were that the 
patient groups are highly selected and not population based, which might have 
led to a selection bias. The number of patients included was also limited for 
practical reasons.  
6.6.2 Oral peanut challenges 
All children in study population 1 underwent DBPCFC. The challenge medium 
recipe of chocolate balls was scientifically evaluated and contained low levels of 
low levels of fat (7%). The completeness of challenge testing and the well-
characterized challenge medium are two major strengths (128, 174). Another 
strength is that all challenges were observed and severity scored by the same 
senior physician. Thus, it is a subjective judgment when objective symptoms 
occur but also a subjective decision when the challenge is stopped (136). A 
limitation is the severity scoring, since the score system used did not differentiate 
OAS (subjective symptoms) from no objective symptoms and furthermore there 
were no scoring for late reactions. The children in our study were allowed to eat 
breakfast before the challenges, which may have interfered with the challenge 
outcome since a large amount of fat eaten before challenge may lead to a milder 
reaction at challenge.  
In paper II we compared the reaction to a DBPCFC with a repeated active 
challenge to peanut (SBFC). This challenge was blinded for the patients and the 
parents, but the doctor and the nurses knew that the challenge was active. This 
knowledge might lead to bias; if the previous reaction had been severe the doctor 
may have been more careful about provoking objective symptoms at the second 
active challenge. Another limitation is that children who reacted with severe 
symptoms at the first challenge were excluded for ethical reasons and did not 
perform a second active challenge. This might have skewed the results since we 
do not know how children with severe symptoms would have reacted at a 
repeated challenge.  
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We decided not to use DBPCFC when diagnosing peanut allergy in study 
population 2, which is a limitation. However, we investigated children with 
suspected cross-reactivity to peanut and did not expect any objective symptoms 
at challenges. OFC is less time consuming and the method is has also been 
accepted if the outcome of the food challenge is negative (101, 175). However, if 
an objective reaction had occurred during OFC, a DBPCFC would have been 
performed.  
6.6.3 CD-sens 
Major strengths of the CD-sens method are that the basophil threshold sensitivity 
is measured at eight different concentrations and that this can be done without 
any risk for the patient. Another strength is that it is possible to use the same 
peanut raw material in CD-sens as is used in the oral challenges. 
Limitations of the CD-sens method are the presence of non-responders and low 
responders. Other limitations are that the CD-sens method is analyzed manually 
and the method is only used in a few laboratories in Sweden. Furthermore, since 
it is a new method, no reference values have been established at the time of these 
studies. Compared to component resolved diagnostics it is an expensive method. 
However, the outcome of the test result may be more clinically relevant since the 
CD-sens assay is a functional assay in contrast to CRD which only shows 
presence/absence of IgE-ab. 
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7 ETHICAL CONSIDERATIONS 
The studies in this thesis were all approved by the Regional Ethical Review 
Board at Karolinska Institutet in Stockholm, Sweden and the studies were 
performed according to good clinical practice based on the Helsinki declaration 
for clinical investigations. All parents and children gave their informed written 
consent to participate in the studies before inclusion. They were informed about 
the study design and the purpose of the study by telephone, and written 
information was sent home before they began participating in the study. If they 
agreed to participate an appointment was booked with the doctor and the family 
was free to ask questions. They were also informed that they could withdraw 
from the study at any time without any effect on future treatment or care.  
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8 CONCLUSSION 
The results of this thesis highlight different diagnostic methods available for a 
proper peanut diagnosis. 
Based on the studies presented, the following conclusion can be drawn: 
• CD-sens is a promising diagnostic method with good reproducibility in 
the diagnosis of peanut allergy and may exclude a peanut allergy.  
 
• An oral peanut challenge can discriminate between a positive and 
negative challenge outcome, but does not predict the severity of an 
allergic reaction. 
 
• Component resolved diagnostics is a valuable diagnostic tool in peanut 
allergy diagnosis since eleveted concentration of IgE-ab to the peanut 
storage proteins (Ara h 1, Ara h 2 and Ara h 3) is associated with peanut 
allergy.  
 
• Birch-pollen allergic children IgE-sensitized to peanut (only to Ara h 8) 
have basophils sensitized with Ara h 8 IgE-ab which can be activated by 
Ara h 8 proteins and initiate allergic inflammation. 
 
• Peanut tolerant children IgE-sensitized to peanuts are characterized by 
low levels of IgG4-antibodies but relatively high IgG4-/IgE-antibody ratio 
to peanut and Ara h 2. 
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9 CLINICAL IMPLICATIONS AND FUTURE 
PERSPECTIVES 
 
DBPCFC is considered the gold standard for diagnosis of peanut allergy, but 
food challenges are time consuming and risky for the patients. Therefore, CD-
sens and CRD may contribute with valuable information in peanut allergy 
diagnosis. CRD can distinguish between genuine peanut allergy and cross-
sensitization to the peanut and thus reduce unnecessary anxiety. In individuals 
IgE-sensitized to peanut, CD-sens may distinguish between presence and 
absence of tolerance and if CD-sens is negative the probability for an allergic 
reaction is low. 
CD-sens has also proven to be a good biological marker for immunological 
changes during allergen specific immunotherapy (176). Therefore CD-sens may 
be used to select patients with high allergen threshold sensitivity to a food 
allergen, i.e. those who are likely to benefit from oral immunotherapy. In 
addition, the response to oral immunotherapy may also be monitored with CD-
sens (176, 177). Another potential use for CD-sens may be to select and follow 
patients who would benefit from Omalizumab treatment. The current indication 
for Omalizumab is severe allergic asthma and chronic urticaria. Dosing of 
Omalizumab is based on concentration of serum IgE and body weight. However, 
CD-sens has potential as a way to follow Omalizumab treatment and may be a 
better way to evaluate treatment response (178-181).  
CRD has already been introduced into clinical practice and has improved the 
diagnostic opportunities in peanut allergy, but more research is needed to 
investigate the clinical use of CD-sens. Cross-sensitization between different tree 
nuts is common and could be an interesting research area to explore both with 
CRD and the CD-sens method. It is also of great interest to continue evaluating 
the CD-sens method in comparison with oral food challenges in food allergic 
children.  
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10 SVENSK SAMMANFATTNING 
Bakgrund: Jordnötsallergi kan orsaka svåra, ibland livshotande reaktioner. Att vara 
allergisk mot ett födoämne innebär att immunförsvaret reagerar på ett i vanliga fall 
ofarligt ämne och bildar allergiantikroppar (IgE-antikroppar). Individer med benägenhet 
att bilda allergiantikroppar kan bli sensibiliserade om de kommer i kontakt med ämnet, 
vilket vid förnyad kontakt kan leda till en allergisk reaktion. I Västeuropa är ca en 
procent av alla individer jordnötsallergiska, men andelen sensibiliserade är högre och 
varierar mellan en och elva procent i olika studier vilket kan bero på korsreaktioner 
mellan olika proteiner som liknar varandra. I jordnöten finns ett protein (Ara h 8) som 
har liknande proteinstruktur som huvudallergenet i björkpollen (Bet v 1). Följden blir att 
björkpollenallergiska individer kan få allergiantikroppar mot jordnötter 
(korssensibilisering). Dessa individer kan känna klåda i mun och svalg när de äter 
jordnötter, men får sällan svåra allergiska reaktioner. En jordnötsallergi diagnostiseras 
oftast genom anamnes, hudpricktest samt förekomst av IgE-antikroppar i blod mot 
jordnötsextrakt. Då det är svårt att med säkerhet veta vilka individer med IgE-
antikroppar mot jordnöt som har en ”äkta allergi” och därmed riskerar att få en svår 
allergisk reaktion, behöver diagnosen ofta bekräftas med en jordnötsprovokation. En 
provokation är tidsödande och kan medföra svåra allergiska symptom. 
Jordnötsproteinerna, Ara h 1, Ara h 2 och Ara h 3 är stabila lagringsproteiner. IgE-
antikroppar mot dessa kan mätas via ett blodprov och anses vara associerade till 
jordnötsallergi. En annan diagnostisk metod är CD-sens där man fastställer minsta 
mängd jordnötsprotein som stimulerar basofila celler i provrör. De basofila cellerna 
medverkar vid uppkomsten av en IgE-förmedlad allergi och via ett blodprov kan man 
mäta de basofila cellernas känslighet för jordnöt. 
 
 Syfte: Det övergripande syftet med avhandlingen var att utvärdera olika diagnostiska 
metoder hos barn med IgE-antikroppar mot jordnöt som har en misstänkt jordnötsallergi. 
. 
Material och Metoder: Trettioåtta barn med misstänkt genomgick tre provokationer 
blint (jordnötter två gånger och placebo en gång). Vilka symtom barnen fick och 
mängden jordnötter de kunde äta dokumenterades. Blodprov togs vid de två första 
provokationerna för CD-sens och IgE-antikroppsanalys. Vi har även undersökt 
björkpollenallergiska barn med enbart allergiantikroppar mot björk, jordnöt och Ara h 8. 
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Tjugo barn genomförde en öppen jordnötsprovokation och ett blodprov togs för att 
undersöka CD-sens mot jordnöt och Ara h 8. 
 
Resultat: Jordnötsallergiska barn hade förhöjda nivåer av IgE-antikroppar mot 
lagringsproteinerna Ara h 1, Ara h 2 och Ara h 3 samt förhöjda nivåer av CD-sens mot 
jordnöt och Ara h 2. Alla barn som var negativa i CD-sens tolererade jordnötter. Vi 
undersökte även reproducerbarheten hos CD-sens metoden och jordnötsprovokationen 
och fann att CD-sens nivåerna var jämförbara mellan de två mättillfällen medans vid en 
upprepad jordnötsprovokation reagerade endast tre barn med samma svårighetsgrad och 
på samma dos.  Hos de 20 björkpollenallergiska barnen kunde alla äta jordnötter, men 
fem barn fick övergående klåda och obehag i munnen som försvann utan behandling. De 
flesta barn (17/20) reagerade i CD-sens mot Ara h 8 och endast ett barn var positiv i CD-
sens mot jordnöt. I avhandlingen beskrivs också en björkpollenallergisk flicka med 
allergiantikroppar mot Ara h 8 som fick en svår allergisk reaktion efter att ätit 300 g 
jordnötter hemma. Hon hade tidigare genomfört två stycken jordnötsprovokationer 
(6.1g) utan att reagera. Flicka äter fortfarande jordnötter (<40 g) men undviker stora 
mängder. 
 
Slutsats: Utifrån resultatet i denna avhandling verkar CD-sens vara en tillförlitlig 
diagnostisk metod som skulle kunna utesluta en jordnötsallergi. Förekomst av IgE-
antikroppar mot jordnötsproteinerna Ara h 1, Ara h 2 och Ara h 3 bekräftar en 
jordnötsallergi. Såväl en jordnötsprovokation som CD-sens kan avgöra om en individ är 
allergisk eller inte. Däremot går det inte med en jordnötsprovokation att förutsäga 
svårighetsgraden av en allergisk reaktion. Björkpollenallergiska barn har basofila celler 
som kan aktiveras av Ara h 8 proteiner och starta en allergisk inflammation. Att de flesta 
inte reagerar kan troligen bero på att andelen Ara h 8 som finns i rostade jordnötter är 
liten och att den lilla mängden som finns bryts ner i mag-tarmkanalen. Ett stort intag av 
jordnötter hos en björkpollen allergisk individ som har bildat IgE-antikroppar mot 
jordnötter på grund av korssensibilisering skulle kunna utlösa en allergisk reaktion. 
Genom förbättrade diagnostiska metoder kan vi på ett bättre sätt avgöra vilka barn som 
behöver undvika jordnötter. Många barn med misstänkt jordnötsallergi kan friskskrivas 
och därigenom få en förbättrad livskvalitet. 
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